STOCKHOLDERS AGREEMENT among TALECRIS BIOTHERAPEUTICS HOLDINGS CORP. TALECRIS HOLDINGS, LLC and BAYER HEALTHCARE LLC AND ITS AFFILIATES PARTY HERETO Dated as of March 31, 2005

Exhibit 10.16.1

EXECUTION COPY

STOCKHOLDERS AGREEMENT

among

TALECRIS BIOTHERAPEUTICS HOLDINGS CORP.

TALECRIS HOLDINGS, LLC

and

BAYER HEALTHCARE LLC AND ITS AFFILIATES PARTY HERETO

Dated as of March 31, 2005

TABLE OF CONTENTS

	Page

ARTICLE I
DEFINITIONS

SECTION 1.01 Certain Defined Terms	2

ARTICLE II
CERTAIN AGREEMENTS

SECTION 2.01 Redemption of Bayer Shares	10

SECTION 2.02 Limitations on Other Redemptions	13

SECTION 2.03 Preemptive Rights	14

SECTION 2.04 Exchange Rights	15

SECTION 2.05 Material Actions	16

SECTION 2.06 Affiliate Transactions	16

SECTION 2.07 Par Value of Capital Stock	17

SECTION 2.08 Achievement of Annual Sales Targets	17

SECTION 2.09 Restricted Payments	17

SECTION 2.10 Board of Directors	19

ARTICLE III
RESTRICTIONS ON TRANSFER

SECTION 3.01 General Restriction	20

SECTION 3.02 Legends	21

SECTION 3.03 Tag-Along Rights	22

SECTION 3.04 Drag-Along Right	23

SECTION 3.05 Right of First Offer upon Sales of Shares	25

SECTION 3.06 Agreement to be Bound	26

SECTION 3.07 Compliance with Securities Laws	26

ARTICLE IV
REGISTRATION RIGHTS

SECTION 4.01 Demand Registration Rights	27

SECTION 4.02 Piggyback Registration Rights	29

SECTION 4.03 Registration on Form S-3	31

SECTION 4.04 Registration Expenses	31

SECTION 4.05 Registration Procedures	31

SECTION 4.06 Preparation; Reasonable Investigation	34

SECTION 4.07 Indemnification	34

SECTION 4.08 Contribution	36

SECTION 4.09 Nominees of Beneficial Owners	38

ARTICLE V
INFORMATION RIGHTS

SECTION 5.01 Financial Information	38

SECTION 5.02 Requested Information	38

SECTION 5.03 Annual Sales Achievement Information	38

SECTION 5.04 Confidentiality	39

ARTICLE VI
REPRESENTATIONS

SECTION 6.01 Representations of the Company	40

SECTION 6.02 Representations of Talecris LLC	42

SECTION 6.03 Representations of Bayer	43

ARTICLE VII
INDEMNIFICATION

SECTION 7.01 Indemnification	44

SECTION 7.02 Enforcing Claims Under Indemnity	44

SECTION 7.03 Exclusive Remedies	46

SECTION 7.04 Treatment as Boot Adjustments	46

ARTICLE VIII
MISCELLANEOUS

SECTION 8.01 Consent to Assignment	47

SECTION 8.02 Entire Agreement and Amendments	47

SECTION 8.03 Notices	47

SECTION 8.04 Non-Waiver	49

SECTION 8.05 Governing Law, Jurisdiction	49

SECTION 8.06 Dispute Resolution of Accounting Matters	50

SECTION 8.07 Captions	50

SECTION 8.08 Severability	50

SECTION 8.09 Defined Terms	50

SECTION 8.10 Set-Off	50

SECTION 8.11 Counterparts	51

SECTION 8.12 Recapitalizations, Exchanges, Etc. Affecting Common Stock	51

SECTION 8.13 Junior Preferred Stock	51

SCHEDULES

SCHEDULE I	Affiliates of Bayer
SCHEDULE II	Initial Capitalization of the Company

EXHIBITS

EXHIBIT A	Certificate of Incorporation
EXHIBIT B	Certificate of Designations for Series A Senior Convertible Preferred Stock
EXHIBIT C	Certificate of Designations for Series B Senior Convertible Preferred Stock
EXHIBIT D	Certificate of Designations for the Junior Preferred Stock
EXHIBIT E	Purchase Agreement for Junior Secured Convertible Notes
EXHIBIT F	Allocation Schedule
EXHIBIT G	Capital Expenditures Schedule
EXHIBIT H	Production Capacity Schedule
EXHIBIT I	Yield Schedule
APPENDIX I	Earnout Calculations

iii

STOCKHOLDERS AGREEMENT (this “Agreement”), dated as of March 31, 2005 (the “Effective Date”), among TALECRIS BIOTHERAPEUTICS HOLDINGS CORP., a Delaware corporation (the “Company”), TALECRIS HOLDINGS, LLC, a Delaware limited liability company (“Talecris LLC”), BAYER HEALTHCARE LLC, a Delaware limited liability company (“Bayer”), and the Affiliates of Bayer listed on Schedule I hereto (together with Bayer, the “Bayer Parties”). Talecris LLC and the Bayer Parties are collectively referred to as the “Stockholders”. Capitalized terms not defined herein have the meanings assigned to them in the Joint Contribution Agreement (as defined below).

RECITALS

A. As of the Effective Date, the authorized capital stock of the Company consists of:

(i) 100,000,000 shares of Common Stock, par value $0.01 per share (the “Common Stock”), of the Company having the rights and preferences set forth in the Company’s Certificate of Incorporation;

(ii) 5,000,000 shares of Series A Senior Convertible Preferred Stock, par value $0.01 per share (the “Series A Senior Convertible Preferred Stock”), of the Company having the rights and preferences set forth in the Company’s Certificate of Designations for the Series A Senior Convertible Preferred Stock (the “Series A Senior Convertible Preferred Stock Designations”);

(iii) 5,000,000 shares of Series B Senior Convertible Preferred Stock, par value $0.01 per share (the “Series B Senior Convertible Preferred Stock”), of the Company having the rights and preferences set forth in the Company’s Certificate of Designations for the Series B Senior Convertible Preferred Stock (the “Series B Senior Convertible Preferred Stock Designations”); and

(iv) 10 shares of Junior Preferred Stock, par value $0.01 per share (the “Junior Preferred Stock”), of the Company having the rights and preferences set forth in the Company’s Certificate of Designations for the Junior Preferred Stock (the “Junior Preferred Stock Designations”).

B. Pursuant to an Amended and Restated Joint Contribution Agreement, dated as of March 30, 2005 (the “Joint Contribution Agreement”), among Bayer, Talecris LLC, the Company and Talecris Biotherapeutics, Inc., as may be amended from time to time, as of the Effective Date, Bayer and its Affiliates will receive 1,000,000 shares of Common Stock and one share of Junior Preferred Stock and Talecris LLC will receive 100,000 shares of Series A Senior Convertible Preferred Stock. Schedule II sets forth the initial capitalization of the Company as of the Effective Date after giving effect to the issuance of the Common Stock and Junior Preferred Stock to Bayer and its Affiliates and the Series A Senior Convertible Preferred Stock to Talecris LLC pursuant to the Joint Contribution Agreement and shows the Equity Interests of the Company issuable in connection with the Precision Acquisition.

C. As a condition to the consummation of the transactions contemplated by the Joint Contribution Agreement and in order to govern certain of their rights, duties and obligations and the relations among themselves following the consummation of the transactions contemplated thereby, the parties hereto desire to enter into this Agreement.

In consideration of the premises and the mutual agreements and covenants hereinafter set forth, the parties hereto hereby agree as follows:

ARTICLE I

DEFINITIONS

SECTION 1.01 Certain Defined Terms.

As used in this Agreement, the following terms shall have the following meanings:

“Affiliate” of any specified Person means any other Person directly or indirectly controlling or controlled by or under direct or indirect common control with such specified Person. For purposes of this definition, “control” (including, with correlative meanings, the terms “controlling,” “controlled by” and “under common control with”), as used with respect to any Person, shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of such Person, whether through the ownership of Voting Stock, by agreement or otherwise; provided, however, that beneficial ownership of 10% or more of the Voting Stock of a Person shall be deemed to be control; provided, further, that none of the Bayer Parties or any of their Affiliates shall be considered to be an Affiliate of the Company or Talecris LLC or any of their respective Subsidiaries.

“Agreement” has the meaning given such term in the Preamble.

“Ampersand” has the meaning given such term in Section 2.10.

“Ancillary Transactions” means the transactions contemplated by the Precision Acquisition, the Senior Credit Agreement, the Second Lien Credit Agreement and the Purchase Agreement and the issuance of Series A Senior Convertible Preferred Stock, Series B Senior Convertible Preferred Stock and Junior Secured Convertible Notes.

“Annual Achievement” has the meaning set forth in Exhibit D.

“Annual Net Sales” has the meaning set forth in Exhibit D.

“Annual Reduction” has the meaning set forth in Exhibit D.

“Annual Sales Target” has the meaning set forth in Exhibit D.

“Approved Sale” means any transaction or series of related transactions, approved by the Board of Directors of the Company, pursuant to which a Third Party or group of Third Parties acting together acquires (i) Equity Interests of the Company constituting a majority of the

issued and outstanding Voting Stock of the Company (whether by merger, consolidation, sale or transfer of the Company’s Equity Interests, or otherwise) or (ii) all or substantially all of the Company’s assets.

“Bayer” has the meaning set forth in the Preamble.

“Bayer Parties” has the meaning set forth in the Preamble.

“Beneficial Owner” has the meaning given such term in Rules 13d-3 and 13d-5 under the Exchange Act.

“Business Day” means any day that is not a Saturday, a Sunday or a day on which commercial banks in New York City are required or authorized to be closed.

“Cerberus” has the meaning given such term in Section 2.10.

“Change of Control” means any of the following: (i) the sale, assignment, conveyance, transfer, lease or other disposition of all or substantially all of the assets of Parent and its Subsidiaries, taken as a whole, whether in one transaction or a series of related transactions; (ii) the acquisition of Parent by another Person by means of merger or consolidation resulting in the exchange of all or substantially all of the outstanding securities of Parent for securities or consideration issued, or caused to be issued, by the acquiring Person or an Affiliate thereof other than a merger with or into a wholly owned Subsidiary or (iii) the consummation by Parent of a transaction or series of related transactions, including the issuance or sale of capital securities, if immediately after the consummation of such transaction (or, in the case of a series of transactions, the last of such transactions) any Person (other than Cerberus, Ampersand and their respective Affiliates) shall acquire, as a result thereof, more than 50% of the Voting Stock of Parent on a fully diluted basis.

“Commission” means the United States Securities and Exchange Commission, and any successor commission or agency having similar powers.

“Common Share” means any share of Common Stock.

“Common Stock” has the meaning set forth in the Recitals.

“Common Stock Equivalents” means, without duplication with any other Common Stock or Common Stock Equivalents, any shares of any class or series of any securities or any instruments (including debt securities) of the Company directly or indirectly convertible into or exercisable or exchangeable for (or which are convertible into or exercisable or exchangeable for another security or instrument which is directly or indirectly convertible into or exercisable or exchangeable for) Common Stock, whether at the time of issuance or upon the passage of time or the occurrence of future events.

“Company” has the meaning set forth in the Preamble.

“Competitor” means any Person (other than the Company and its Affiliates) that directly or indirectly engages or invests in the business of manufacturing, marketing, distribution, sale and/or research and development of plasma-derived products.

“Confidential Information” has the meaning set forth in Section 5.04(a).

“Delay Notice” has the meaning set forth in Section 4.01(f)(ii).

“Demand Exercise Notice” has the meaning set forth in Section 4.01(a).

“Demanding Party” has the meaning set forth in Section 4.01(a).

“Demand Registration” has the meaning set forth in Section 4.01(a).

“Demand Registration Maximum Offering Size” has the meaning set forth in Section 4.01(g).

“Demand Registration Request” has the meaning set forth in Section 4.01(a).

“Disadvantageous Condition” means the existence of any acquisition, disposition or other material transaction involving the Company or any of its Subsidiaries or any material financing activity, or the unavailability of any required financial statements, or the possession by the Company of material information which would not be in the best interests of the Company or any of its Subsidiaries to disclose in a Registration Statement.

“Disclosing Party” has the meaning set forth in Section 5.04(c).

“Dispute Notice” has the meaning set forth in Section 8.06.

“Drag-Along Notice” has the meaning set forth in Section 3.04(b).

“Drag-Along Sale” has the meaning set forth in Section 3.04(a).

“Effective Date” has the meaning set forth in the Preamble.

“Employee Plan” means any equity incentive plan, agreement, bonus, award, stock purchase plan, stock option plan or other stock arrangement.

“Equity Interests” means any shares of any class or series of any securities or instruments (including debt securities) directly or indirectly convertible into or exercisable or exchangeable for shares of any class or series of capital stock of any Person (or which are convertible into or exercisable or exchangeable for another security or instruments which is, in turn, directly or indirectly convertible into or exercisable or exchangeable for shares of any class or series of capital stock of such Person), whether at the time of issuance or upon the passage of time or the occurrence of future events, whether now authorized or not.

“ERISA” means the Employee Retirement Income Security Act of 1974, as amended from time to time.

“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder.

“Exchange Notice” has the meaning set forth in Section 2.04(c).

“Exchange Share” means any share of Voting Stock of Parent.

“Fully Diluted Common Shares” means, at any time of determination, then outstanding shares of Common Stock plus, without duplication, all shares of Common Stock issuable, whether at such time or upon the passage of time or the occurrence of future events, upon the conversion, exercise or exchange of all then outstanding Common Stock Equivalents.

“Fundamental Change” means any transaction or event (including without limitation any merger, consolidation, sale of assets, tender or exchange offer, reclassification, compulsory share exchange or liquidation) in which all or substantially all outstanding Common Stock is converted into or exchanged for stock, other securities, cash or assets.

“GAAP” means generally accepted accounting principles as in effect from time to time in the United States of America applied on a consistent basis.

“Indebtedness” means, as applied to any Person, without duplication, the following items to the extent properly classified as a liability on a balance sheet prepared in accordance with GAAP (or, with respect to clause (xi), appearing on a balance sheet prepared in accordance with GAAP otherwise than in the stockholders equity section thereof) or disclosed in the footnotes to such Person’s consolidated financial statements prepared in accordance with GAAP: (i) all indebtedness for borrowed money; (ii) that portion of obligations with respect to capital leases, including sale and leaseback obligations, that is properly classified as a liability on a balance sheet in accordance with GAAP; (iii) notes payable and drafts accepted representing extensions of credit whether or not representing obligations for borrowed money (excluding accounts payable which are classified as current liabilities in accordance with GAAP and accrued expenses in each case incurred in the ordinary course of business); (iv) any obligation owed for all or any part of the deferred purchase price of property or services (excluding any such obligations incurred under ERISA or with respect to earn outs incurred and paid when due in connection with an acquisition), which purchase price is-evidenced by a note or similar written instrument (including, without limitation, any accrued management fees payable by the Company which are not yet paid as a result of restrictions in any then existing agreement prohibiting the Company from making such payment); (v) all indebtedness secured by any Lien on any property or asset owned or held by that Person regardless of whether the indebtedness secured thereby shall have been assumed by that Person or is nonrecourse to the credit of that Person; (vi) the face amount of any letter of credit issued for the account of that Person or as to which that Person is otherwise liable for reimbursement of drawings; (vii) the direct or indirect guaranty, endorsement (otherwise than for collection or deposit in the ordinary course of business), co-making, discounting with recourse or sale with recourse by such Person of the obligation of another that constitutes Indebtedness under another clause of this definition; (viii) any obligation of such Person the primary purpose or intent of which is to provide assurance to an obligee that the obligation of the obligor thereof will be paid or discharged, or any agreement relating thereto will be complied with, or the holders thereof will be protected (in

whole or in part) against loss in respect thereof; (ix) any liability of such Person for an obligation of another through any agreement (contingent or otherwise) that constitutes Indebtedness under another clause of this definition (a) to purchase, repurchase or otherwise acquire such obligation or any security therefor, or to provide funds for the payment or discharge of such obligation (whether in the form of loans, advances, stock purchases, capital contributions or otherwise) or (b) to maintain the solvency or any balance sheet item, level of income or financial condition of another if, in the case of any agreement described under subclauses (a) or (b) of this clause (ix), the primary purpose or intent thereof is as described in clause (viii) above; (x) the notional amount of all obligations of such Person in respect of any exchange traded or over the counter derivative transaction, including, without limitation, interest rate protection agreement, foreign currency exchange agreement and other interest or exchange rate hedging arrangement, whether entered into for hedging or speculative purposes; and (xi) the liquidation preference of mandatorily redeemable, nonconvertible preferred stock (other than the Junior Preferred Stock).

“Initial Common Shares” means the Common Shares issued to Bayer and its Affiliates as of the date hereof, as adjusted for any stock splits, stock dividends, combinations, reclassifications or reverse stock splits in respect of such Common Shares occurring during the period between the date hereof and the Redemption Date.

“Initial Shares” has the meaning set forth in Section 4.05(e).

“IPO” means the initial public offering, if any, of Equity Interests of the Company or Parent pursuant to an effective Registration Statement under the Securities Act.

“Joint Contribution Agreement” has the meaning set forth in the Recitals.

“Joint Notice” has the meaning set forth in Section 3.05(b).

“Junior Preferred Stock” has the meaning set forth in the Recitals.

“Junior Preferred Stock Designations” has the meaning set forth in the Recitals.

“Junior Secured Convertible Notes” means the Junior Secured Convertible Notes due 2013 of the Company.

“Lien” means, with respect to any property or other asset of any Person (or any revenues, income or profits of that Person therefrom) (in each case whether the same is consensual or nonconsensual or arises by contract, operation of law, legal process or otherwise), (i) any mortgage, lien, security interest, pledge, assignment, hypothecation, title retention, preferential right, counterclaim, attachment, actual, planned or threatened expropriation, seizure, embargo, levy or other charge or encumbrance of any kind thereupon or in respect thereof or (ii) any other arrangement under which the same is transferred, sequestered or otherwise identified with the intention of subjecting the same to, or making the same available for, the payment or performance of any liability in priority to the payment of the ordinary, unsecured creditors of that Person. For purposes of this Agreement, a Person will be deemed to own subject to a Lien any asset that it has acquired or holds subject to the interest of a vendor or lessor under any conditional sale agreement, capital lease, synthetic lease or other title retention agreement relating to that asset.

“NASD” means the National Association of Securities Dealers, Inc.

“Net Proceeds” means, with respect to a sale of Equity Interests by the Company, the aggregate net proceeds received by the Company, after payment of commissions, discounts and expenses incurred in connection with such sale, whether in cash or in property (which shall be valued at the fair market value thereof as determined by the Board of Directors of the Company in good faith).

“New Issue Securities” has the meaning set forth in Section 2.03(a)(i).

“Notice of Acceptance” has the meaning set forth in Section 2.03(b).

“Notice of Objection” has the meaning set forth in Section 2.04(c).

“Notice of Interest” has the meaning set forth in Section 3.03(b).

“Notice Period” has the meaning set forth in Section 3.03(b).

“Offer Period” has the meaning set forth in Section 3.05(b).

“Offer Terms” has the meaning set forth in Section 3.05(a).

“Offered Shares” has the meaning set forth in Section 3.05(a).

“Overallotment Option Shares” has the meaning set forth in Section 4.05(e).

“Parent” means Talecris LLC, any successor to Talecris LLC or any direct or indirect upstream parent entity holding a controlling interest in the Equity Interests of Talecris LLC other than Cerberus, Ampersand and their related funds.

“Parent Equity Valuation” has the meaning set forth in Section 2.04(c).

“Permitted Transferee” shall mean, with respect to any Bayer Party, (i) the Company or Talecris LLC or (ii) any Affiliate of ▇▇▇▇▇ ▇▇, a stock corporation organized under the laws of the Federal Republic of Germany.

“Person” means any individual, corporation (including not-for-profit), general or limited partnership, limited liability company, joint venture, association, joint-stock corporation, estate, trust, unincorporated organization or government or any political subdivision, agency or instrumentality thereof or any other entity of any kind.

“Piggyback Registration Maximum Offering Size” has the meaning set forth in Section 4.02(b).

“Precision Acquisition” means the acquisition by Talecris LLC or the Company, directly or indirectly through its Affiliates, of substantially all the stock or assets of Precision Pharma Services, Inc.

“Preemptive Offeree” has the meaning set forth in Section 2.03(a)(i).

“Preemptive Rights Notice” has the meaning set forth in Section 2.03(a)(ii).

“Preemptive Share” has the meaning set forth in Section 2.03(a)(ii).

“Pro Rata Share” has the meaning set forth in Section 3.03(b).

“Prospectus” means the prospectus included in a Registration Statement, including any preliminary prospectus or summary prospectus, and any such prospectus or preliminary or summary prospectus as amended or supplemented, and in each case including all material incorporated by reference therein.

“Public Offering” means an underwritten public offering of common stock of a Person that is a corporation (or Equity Interests of a Person that is not a corporation comparable to common stock) pursuant to an effective Registration Statement under the Securities Act.

“Purchase Agreement” means the Purchase Agreement dated as of March 31, 2005 between the Company and Talecris LLC with respect to the purchase of the Junior Secured Convertible Notes.

“Qualified Public Offering” means an IPO in which the aggregate net proceeds, after deducting underwriters’ discounts and commissions and offering expenses, to the Company and/or Parent equal or exceed US $75 million.

“Registrable Securities” means the Shares held by the parties to this Agreement or by any other Persons to whom incidental registration rights may be granted after the date hereof. As to any particular Registrable Securities that have been issued, such securities shall cease to be Registrable Securities when (i) a Registration Statement with respect to the sale of such securities shall have become effective under the Securities Act and such securities shall have been disposed of under such Registration Statement; (ii) they shall have been distributed to the public pursuant to Rule 144; (iii) they shall have been otherwise transferred or disposed of, and new certificates therefor not bearing a legend to the effect set forth in the first paragraph of the legend required by Section 3.02 restricting further transfer shall have been delivered by the Company, and subsequent transfer or disposition of them shall not require their registration or qualification under the Securities Act or any state securities laws or (iv) they shall have ceased to be outstanding.

“Registration Expenses” has the meaning set forth in Section 4.04.

“Registration Statement” means a registration statement filed by an issuer with the Commission and all amendments and supplements to any such registration statement, including post-effective amendments, in each case including the Prospectus contained therein, all exhibits thereto and all material incorporated by reference therein.

“Representatives” has the meaning set forth in Section 5.04(a).

“Restricted Payments” has the meaning set forth in Section 2.09.

“Reviewing Accountant” has the meaning set forth in Section 8.06.

“Roll-Up” has the meaning set forth in Section 2.04(b).

“Rule 144” means Rule 144 (or any successor provision) under the Securities Act.

“Sale” means any sale of legal and beneficial ownership of Shares for value. The terms “Sell” and “Sold” have corresponding meanings.

“Sales Target Year” has the meaning set forth in Exhibit D.

“Second Lien Credit Agreement” means the Second Lien Credit Agreement dated as of March 31, 2005 among the Company, its Subsidiaries, Cerberus-Plasma Holdings LLC and the lenders party thereto.

“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations thereunder.

“Selling Party” has the meaning set forth in Section 3.05(a).

“Selling Party’s Notice” has the meaning set forth in Section 3.05(a).

“Senior Convertible Preferred Stock” means the Series A Senior Convertible Preferred Stock and Series B Senior Convertible Preferred Stock collectively.

“Senior Credit Agreement” means the Credit Agreement dated as of March 31, 2005 among the Company, its Subsidiaries, JPMorgan Chase Bank, N.A. and the lenders party thereto.

“Series A Senior Convertible Preferred Stock Designations” has the meaning set forth in the Recitals.

“Series B Senior Convertible Preferred Stock Designations” has the meaning set forth in the Recitals.

“Share” means any Common Share or any share of Senior Convertible Preferred Stock.

“Stockholder” has the meaning set forth in the Preamble.

“Subsidiary” of any Person means (i) a corporation more than 50% of the outstanding Voting Stock of which is owned, directly or indirectly, by such Person or by one or more other Subsidiaries of such Person or by such Person and one or more Subsidiaries thereof or (ii) any other Person (other than a corporation) in which such Person or one or more other Subsidiaries of such Person or such Person and one or more other Subsidiaries thereof, directly or indirectly, has at least majority ownership and the power to direct the management or policies thereof.

“Tag-Along Offer Notice” has the meaning set forth in Section 3.03(a).

“Tag-Along Offer Price” has the meaning set forth in Section 3.03(a).

“Tag-Along Right” has the meaning set forth in Section 3.03(a).

“Tag-Along Shares” has the meaning set forth in Section 3.03(a).

“Tag-Along Stockholder” has the meaning set forth in Section 3.03(a).

“Tag-Along Transfer” has the meaning set forth in Section 3.03(a).

“Talecris Inc.” means Talecris Biotherapeutics, Inc., a Delaware corporation.

“Talecris LLC” has the meaning set forth in the Preamble.

“Third Party” means, with respect to any Stockholder, any Person other than such Stockholder, any Affiliate of such Stockholder or another Stockholder.

“Transfer” means any transfer, Sale, assignment, distribution, exchange, charge, pledge, gift, hypothecation, conveyance, encumbrance, security interest or other disposition of Shares or of a participation or other rights therein (including any contract therefor), whether direct or indirect or through any one or more intermediaries, voluntary or involuntary, by transfer by reorganization, merger, sale of substantially all of the assets or by operation of law, or for value or otherwise, or the entering into of a transaction or other arrangement by a Stockholder which has, or is intended to have, the effect of transferring any economic benefit and/or risks of the ownership of the Shares, or the entering into of any voting trust or other arrangement (other than as contemplated herein) with respect to voting rights of such Shares, or the transfer of an interest in any Person holding the Shares (directly or indirectly through any other Person in which such first-named Person holds an interest) or having other economic interest, direct or indirect, in the Shares. Any indirect Transfer shall include the transfer of any direct or indirect economic or beneficial interest in the Shares that would result in the transferee having the opportunity, directly or indirectly, to profit or share in any profit derived from a transaction in the Shares.

“Valuation Firm” has the meaning set forth in Section 3.05(g).

“Voting Stock” of any Person means capital stock of such Person which ordinarily has voting power for the election of directors (or persons performing similar functions) of such Person.

ARTICLE II

CERTAIN AGREEMENTS

SECTION 2.01 Redemption of Bayer Shares.

(a) At any time from the date five years after the Effective Date up to and until the termination of this Section 2.01 (the “Put Period”), the Bayer Parties collectively may elect to cause the Company to redeem the Initial Common Shares, in whole but not in part, at the Put Price.

(b) At any time from and after the date two years after the Effective Date up to and until the termination of this Section 2.01 (the “Call Period”), the Company may elect to redeem the Initial Common Shares, in whole but not in part, at the Call Price.

(c) In the event that the Bayer Parties, on the one hand, and the Company, on the other hand, simultaneously make an election pursuant to Section 2.01(a) and Section 2.01(b), respectively, the election made by the Company shall control.

(d) Any election pursuant to Section 2.01(a) or Section 2.01(b) shall be made by the electing party by giving to the other party a written notice of such election (the “Notice of Election”), which election shall be irrevocable at the time of such notice (the “Election Time”). The Notice of Election shall state the Redemption Date and, in the case of a redemption pursuant to Section 2.01(b), the Call Price.

(e) The Put Price and the Call Price shall be payable in cash only out of funds legally available to distribute to the Company’s equity holders on a day that is no more than 45 days after the Election Time (the “Redemption Date”). The Company may not elect to redeem the Initial Common Shares if the Board of Directors of the Company determines, after consultation with its outside legal and financial advisors, that it will not have funds legally available therefor on the Redemption Date. If on the Redemption Date with respect to an election pursuant to Section 2.01(a), the Company does not have funds legally available for the payment of the Put Price, the Company shall provide the Bayer Parties with a schedule of its calculation of the amount of funds legally available therefor. If sufficient funds are not legally available, then (i) the Bayer Parties may, in their sole discretion, elect to have the Company redeem as many of the Bayer Parties’ respective Initial Common Shares as such funds will allow or to withdraw the Notice of Election, (ii) all transfer restrictions set forth in Section 3.01 and the right of first offer set forth in Section 3.05 shall lapse in their entirety as to any Initial Common Shares that are not able to be redeemed and (iii) at any time thereafter when additional funds of the Corporation are legally available for the redemption of the Initial Common Shares, such funds will be used at the earliest permissible time to redeem or pay the balance of such shares, or such portion thereof for which funds are then legally available. For the avoidance of doubt, all references to funds “legally available” in this Article II shall mean those funds available under and pursuant to Section 160 of the Delaware General Corporation Law or any provision successor thereto. If, for any reason, the Company fails to redeem all Initial Common Shares on the Redemption Date, (i) the unredeemed shares shall remain outstanding and shall continue to have all rights provided for herein, (ii) the holders of such unredeemed shares shall have the ongoing right to be redeemed together with such rights and remedies as may be available under applicable law, (iii) the Company shall not pay any dividends on, or otherwise make any distributions to the holders of, any shares of Senior Convertible Preferred Stock or other Equity Interests of the Company then held by Talecris LLC or its Affiliates or any cash payment on the Junior Secured Convertible Notes or any other Indebtedness of the Company then owed to Talecris LLC or its Affiliates (other than cash payments between the Company and its consolidated Subsidiaries) or any advances or loans or other cash payments to Talecris LLC or its Affiliates (other than advances or loans between the Company and its consolidated Subsidiaries), in each case until all amounts due to the holders of the Initial Common Shares are paid in full, (iv) the failure to redeem on the Redemption Date shall constitute a breach of this Agreement and non-performance of the mandatory redemption covenant and it shall be no

defense thereto that there are restrictive covenants in any other agreement prohibiting any such mandatory redemption, and (v) the Corporation shall not redeem any shares of its capital stock until the Junior Preferred Stock has been redeemed in full; provided, however, that notwithstanding the provisions of this Section 2.01(e), the Company may (a) pay any and all of its obligations owing to the lenders pursuant to the Senior Credit Agreement and the Second Lien Credit Agreement, as such Senior Credit Agreement or Second Lien Credit Agreement may be amended, extended, renewed, refinanced or replaced, provided that such payments may not be made to Talecris LLC or its Affiliates to the extent that the principal amount of Indebtedness then owed to Talecris LLC or its Affiliates, incurred pursuant to any such amendment, extension, renewal, refinancing or replacement, exceeds the principal amount of the Indebtedness owed to Talecris LLC or its Affiliates pursuant to the Credit Agreement or the Second Lien Credit Agreement prior to such amendment, extension, renewal, refinancing or replacement, as applicable, plus the amount of interest, fees, premiums and other expenses payable in connection with such amendment, extension, renewal, refinancing or replacement, and (b) redeem or repurchase any Shares to the extent permitted by Section 2.02(c).

(f) On the Redemption Date, (i) the Bayer Parties shall deliver to the Company certificates representing such Bayer Parties’ respective Initial Common Shares, (ii) Bayer and the Company shall execute such instruments and agreements as are customary under the circumstances (which agreements shall include a representation and warranty by such Bayer Parties that, assuming that the Company has no knowledge of any adverse claim to the Shares or Exchange Shares, the Company will acquire such securities free of adverse claims) and (iii) the Company shall pay the Put Price or the Call Price, as applicable, for such Shares to such Bayer Parties in immediately available funds.

(g) The “Put Price” shall be $15 million (or, if greater, 10% of the amount of cash contributed by Talecris LLC to the Company on or prior to the Effective Time in exchange for Common Stock or Common Stock Equivalents), plus 6% per annum, compounded annually, thereon from the Effective Date to the Redemption Date.

(h) The “Call Price” shall be, at the applicable Election Time, the greater of (a) $15 million, plus 6% per annum, compounded annually, thereon from the Effective Date to the Redemption Date and (b) the Bayer Equity Fair Market Value. The “Bayer Equity Fair Market Value” at any time shall be the Bayer Equity Percentage multiplied by the Deemed Equity Value at such time. The “Bayer Equity Percentage” at any time shall be the amount equal to (i) the total number of outstanding Initial Common Shares held by the Bayer Parties divided by (ii) the number of Fully Diluted Common Shares. Solely for purposes of calculating the Bayer Equity Percentage, the number of outstanding Initial Common Shares held by the Bayer Parties shall be deemed adjusted in accordance with the adjustment provision in Section 7(d)(iii) of each of the Series A Senior Convertible Preferred Stock Designations and Series B Senior Convertible Preferred Stock Designations, as such section may be amended from time to time; provided, however, that (1) no such adjustment shall be deemed made to the extent that the Bayer Parties were offered the right to purchase their Preemptive Share of the Common Shares so issued or granted pursuant to Section 2.03 and, if the Bayer Parties did not exercise such right, there was no adjustment to the then applicable conversion rate of the Series A Senior Convertible Preferred Stock or Series B Senior Convertible Preferred Stock in connection with such issuance or grant and (2) no such adjustment shall be deemed made in connection with issuance of New

Issue Securities described in clause (i), (ii) or (iv) of Section 2.03(d) provided that any issuance of New Issue Securities described in clause (iv) of Section 2.03(d) to lenders or purchasers that are Affiliates of the Company is in compliance with Section 2.06. The “Deemed Equity Value” at any time shall be the amount equal to (i) 47% of the consolidated net sales, after reduction for discounts, allowances and rebates, of the Company, determined in accordance with GAAP, for the four consecutive fiscal quarters ended immediately prior to such time, minus (ii) the amount of Indebtedness of the Company and its consolidated subsidiaries outstanding at such time; provided, however, that solely for purposes of the calculation of the Deemed Equity Value, all outstanding convertible debt shall be deemed converted and the term “Indebtedness” shall not include any amounts outstanding under such debt; provided, further, that solely for purposes of the calculation of the Deemed Equity Value, Indebtedness shall be net of cash and cash equivalents held by the Company. In the event of an Exchange, the Bayer Equity Fair Market Value shall be adjusted consistent with Section 2.04(c). Any dispute as to the calculation of the Bayer Equity Fair Market Value shall be resolved pursuant to Section 8.06.

(i) This Section 2.01 shall terminate immediately prior to the consummation of a Qualified Public Offering.

(j) In determining the amount of funds legally available per subsection (e) for the redemption provided in this Section 2.01 or for the redemption of the Junior Preferred Stock, the Company shall value its assets at the highest amount determined by the Board of Directors of the Company or the Board of Managers or similar body of Parent, as the case may be, after consultation with its outside legal and financial advisors, to be legally available.

SECTION 2.02 Limitations on Other Redemptions.

(a) No shares of capital stock of the Company shall be redeemable or purchased by the Company other than the Junior Preferred Stock prior to the Call Period, unless the Company offers to purchase concurrently the Common Shares held by the Bayer Parties on a pro rata basis. During the Call Period, no Shares other than Common Shares or shares of Junior Preferred Stock held by the Bayer Parties shall be redeemable or purchased by the Company until the earlier of (i) the closing of a put by the Bayer Parties pursuant to Section 2.01(a), (ii) the expiration of the Put Period if the Bayer Parties have not delivered the Notice of Election pursuant to Section 2.01(a) prior to such expiration and (iii) the consummation of a Qualified Public Offering.

(b) Without limiting the provisions in Section 2.02(a), if the Company proposes to redeem any shares of its capital stock other than Common Shares or shares of Junior Preferred Stock held by the Bayer Parties, it shall not redeem such Shares if any such redemption will impair the Company’s ability to redeem the Junior Preferred Stock in full.

(c) Notwithstanding the provisions of Sections 2.02(a) and 2.02(b), the Company may (i) redeem or repurchase any Shares from officers, former officers, employees, former employees, directors or former directors of the Company or its Affiliates upon the death, disability or termination of the employment of such officers, former officers, employees or former employees or termination of the term of such director or former director and (ii) redeem or repurchase Shares deemed to occur upon (A) the exercise of stock options if such Shares

represent a portion of the exercise price thereof and (B) the withholding of a portion of the Shares granted or awarded to an employee to pay taxes associated therewith.

SECTION 2.03 Preemptive Rights.

(a) Subject to the exceptions set forth in Section 2.03(d), the Company shall:

(i) not issue, sell or exchange, agree or obligate itself to issue, sell or exchange, or reserve or set aside for issuance, sale or exchange any Equity Interests of the Company unless the Company shall have first offered to sell such securities (the “New Issue Securities”) to each Stockholder (in each case, a “Preemptive Offeree”) in accordance with this Section 2.03; and

(ii) offer to sell each Preemptive Offeree all or any portion of its Preemptive Share of any proposed issuance of New Issue Securities at the same price and on the same terms at which the Company proposes to sell such New Issue Securities, which shall have been specified by the Company in a written offer delivered to the Preemptive Offerees setting forth all of the terms and conditions of the offering of the New Issue Securities (the “Preemptive Right Notice”), which offer by its terms shall remain open and irrevocable for a period of 15 Business Days from receipt of the Preemptive Right Notice. The offer of the Company to sell the New Issue Securities shall expire after such 15-Business Day period. “Preemptive Share” shall equal (i) the number of shares of New Issue Securities multiplied by (ii) a fraction (A) the numerator of which is equal to the number of Fully Diluted Common Shares that would be owned by such Stockholder assuming the conversion, exercise or exchange of all Equity Interests of the Company owned by such Stockholder and (B) the denominator of which is equal to the Fully Diluted Common Shares.

(b) Within 15 Business Days after receipt of the Preemptive Right Notice, the Preemptive Offeree may give notice to the Company of its intent to accept (a “Notice of Acceptance”) the Company’s offer to purchase all or any portion of its Preemptive Share of New Issue Securities, which Notice of Acceptance shall constitute an irrevocable acceptance of such offer. If the Company does not receive a Notice of Acceptance within such 15-Business Day period with respect to any New Issue Securities, such Preemptive Offeree shall be deemed to have waived its opportunity to purchase such New Issue Securities, and the Company shall be free to issue and sell such New Issue Securities (or other securities convertible into or exercisable or exchangeable for such New Issue Securities) to any Person on terms and conditions which, taken as a whole, are no less favorable to the Company, at any time within 180 days after the expiration of such 15-Business Day period. Any New Issue Securities not sold within 180 days after the expiration of such 15-Business Day period shall continue to be subject to the requirements of this Section 2.03.

(c) Upon the closing of any such purchase of New Issue Securities, which shall include full payment to the Company of the purchase price therefor, each Preemptive Offeree shall purchase from the Company, and the Company shall sell to such Preemptive Offeree, the number of New Issue Securities specified in the Preemptive Offeree’s Notice of Acceptance, upon the terms and conditions specified in the Preemptive Right Notice.

(d) The rights of the Preemptive Offerees under Section 2.03(a) shall not apply to any of the following New Issue Securities:

(i) options or other Common Stock Equivalents to purchase up to 3,333,333 shares of Common Stock (which shall be reduced by the shares of Common Stock issuable pursuant to the Precision Acquisition) issued to the Company’s or its Subsidiaries’ employees, consultants, directors or officers pursuant to stock option, stock purchase, restricted stock or similar equity or incentive-based compensation plans or agreements approved by the Company’s Board of Directors;

(ii) New Issue Securities issued in connection with an IPO;

(iii) New Issue Securities issued pursuant to the exercise, conversion or exchange of any then outstanding convertible or exchangeable securities, rights, options or warrants, including without limitation, the Senior Convertible Preferred Stock issued to Talecris LLC;

(iv) New Issue Securities issued to lenders or purchasers of debt securities of the Company or Parent or their Subsidiaries in connection with debt incurred to such lenders or purchasers;

(v) New Issue Securities issued in consideration of an acquisition of the equity or assets of another Person, whether by sale, consolidation, merger or other similar transaction; and

(vi) New Issue Securities issued as dividends or distributions generally to holders of Shares (including holders of Common Stock), or upon any subdivision or combination or similar recapitalization of Shares.

(e) This Section 2.03 shall terminate immediately prior to the consummation of an IPO.

SECTION 2.04 Exchange Rights.

(a) Immediately prior to the consummation of an IPO of Parent or Change of Control of Parent, the Bayer Parties, on the one hand, and Talecris LLC, on the other hand, will each be entitled to cause the Common Shares held by the Bayer Parties to be exchanged for Equity Interests in Parent as comparable as practicable to the Common Stock. No such exchange rights will apply to shares of Junior Preferred Stock.

(b) In the event Parent elects to cause the Company to become a wholly owned subsidiary of Parent (a “Roll-Up”), Talecris LLC will be entitled to (i) cause the Common Shares to be exchanged for Equity Interests in Parent as comparable as practicable to the Common Stock (and in any event having a value no less, and terms no less favorable to the Bayer Parties, than those of their Common Shares) and (ii) cause the shares of Junior Preferred Stock held by the Bayer Parties to be exchanged for Equity Interests in Parent having identical rights and privileges to the Junior Preferred Stock except as otherwise agreed by Bayer.

(c) As soon as practicable and no fewer than 90 days prior to the consummation of an IPO or Change of Control of Parent or a Roll-Up, Talecris LLC will deliver to each Bayer Party written notice of such proposed IPO, Change of Control or Roll-Up (“Exchange Notice”), specifying the material terms thereof and whether Talecris LLC is exercising its right to require the Shares held by the Bayer Parties to be exchanged for Equity Interests in Parent. The parties shall negotiate in good faith to determine the relative value of the Common Shares and the Equity Interests of Parent into which the Common Shares will be exchanged. During the course of the negotiations, Talecris LLC shall make available to the Bayer Parties and their representatives such current financial, sales and other information as Bayer may reasonably request for purposes of determining such value. If Talecris LLC and Bayer are unable to reach agreement as to such value within 60 days after the Bayer Parties’ receipt of the Exchange Notice, then they shall submit the dispute to a mutually agreed, nationally recognized investment banking firm which will perform such relative valuation, which valuation will be binding on the parties. Talecris LLC and Bayer shall each pay 50% of the fees and expenses of such firm.

(d) Consistent with Section 8.12, upon the consummation of any exchange pursuant to Section 2.04(a) or Section 2.04(b), the provisions of this Agreement shall be adjusted such that references in this Agreement to Shares shall be deemed to be references to the Exchange Shares, and references in this Agreement to the Company shall be deemed to be references to Parent.

SECTION 2.05 Material Actions.

The Company shall not, without the prior written consent of the Bayer Parties owning a majority of the outstanding shares of the relevant class, (a) amend the Certificate of Incorporation or Bylaws of the Company so as to adversely alter or change the preferences, rights, privileges or powers or the restrictions provided for the benefit of holders of Common Stock and Junior Preferred Stock or (b) create or issue any other classes of common stock.

SECTION 2.06 Affiliate Transactions.

(a) The Company will not engage in any transaction with Cerberus or Ampersand or their respective Affiliates, unless (i) such transaction or series of related transactions is on terms no less favorable to the Company than those available from a Third Party and (ii)(A) if such transaction or series of related transactions has a value in excess of $1 million, it is approved by a disinterested majority of the Board of Directors of the Company and (B) if such transaction has a value in excess of $10 million, the Board of Directors of the Company receives from a nationally recognized investment banking or appraisal firm a written opinion that the transaction is fair to the Company and its stockholders (for the avoidance of doubt, holders of Junior Preferred Stock are stockholders of the Company for purposes of the foregoing) from a financial point of view; provided, however, that this Section 2.06(a) shall not apply to issuances of Equity Interests of the Company if the Company has complied with the provisions of Section 2.03, except that this Section 2.06(a) shall apply to issuances of Equity Interests of the Company pursuant to Section 2.03(d)(iv) or Section 2.03(d)(v) other than, in the case of Section 2.03(d)(v), as the consideration for the Precision Acquisition; and provided further, this

Section 2.06(a) shall not apply to transactions between the Company and any of its wholly owned Subsidiaries.

(b) Section 2.06(a) shall not apply to (i) the payment of principal, premium and interest in respect of Indebtedness incurred in compliance with Section 2.06(a), (ii) the payment of dividends or distributions on any Equity Interests in compliance with this Agreement, (iii) the redemption or repurchase of any Equity Interests in compliance with this Agreement, (iv) the payment of customary and competitive compensation for services provided by employees, officers, directors and consultants to the Company or its Affiliates solely in their capacities as such, (v) the payment of customary and competitive management fees in any year not exceeding 0.5% of the consolidated net sales, after reduction for discounts, allowances and rebates, of the Company for such year as set forth on the financial statements of the Company prepared in accordance with GAAP, and the reimbursement of reasonable out-of-pocket expenses of Cerberus, Ampersand and their respective Affiliates incurred in connection with the transactions contemplated by the Joint Contribution Agreement and the Ancillary Transactions not to exceed $26 million or otherwise incurred directly or indirectly in connection with the business, operations, management or direction of the Company not to exceed $1 million in the first twelve months following the Effective Date and $0.5 million in each twelve-month period thereafter, (vi) the discharge of contractual obligations pursuant to this Agreement, the Joint Contribution Agreement and the other Transaction Documents, and the Ancillary Transactions and (vii) the entering into of agreements with respect to any of the foregoing.

SECTION 2.07 Par Value of Capital Stock.

All capital stock of the Company issued on or before the date of this Agreement has a par value of $0.01 per share. The Company, at the time it issues any shares of capital stock, shall set the par value at $0.01 per share and declare an amount equal to the aggregate par value thereof as stated capital and shall not thereafter increase the capital attributed to such shares.

SECTION 2.08 Achievement of Annual Sales Targets.

The Company shall not act, and shall cause Talecris LLC and Talecris Inc. not to act, in bad faith with the intent of missing the Annual Sales Targets as set forth in the Junior Preferred Stock Designations in order to reduce the Company’s redemption obligations under the Junior Preferred Stock. As of the date hereof, the Company’s general operating strategy is not materially inconsistent with achievement of the Annual Sales Targets; provided, however, that Bayer acknowledges that the Company’s general operating strategy excludes the development, marketing and sale of, and net sales from, Plasmin.

SECTION 2.09 Restricted Payments.

At any time during which shares of Junior Preferred Stock are outstanding, the Company will not declare, pay or make, or agree to pay or make, (i) any cash dividend on the Senior Convertible Preferred Stock or any other Equity Interests of the Company then held by Talecris LLC or its Affiliates, (ii) any cash interest payment on the Junior Secured Convertible Notes or any other Indebtedness of the Company then owed to Talecris LLC or its Affiliates

(other than cash payments between the Company and its consolidated Subsidiaries) or any advances or loans or other cash payments to Talecris LLC or its Affiliates (other than advances or loans between the Company and its consolidated Subsidiaries) or (iii) any cash payment, only to the extent in excess of 100% of the principal amount, on the principal of the Junior Secured Convertible Notes or the principal of any other Indebtedness of the Company then owed to Talecris LLC or its Affiliates (other than cash payments between the Company and its consolidated Subsidiaries) (clauses (i) through (iii) collectively, “Restricted Payments”), except the Company may make Restricted Payments:

(a) in an amount during any year not in excess of the amount of taxes payable during such year by the recipients thereof (or by any Affiliate of such recipients) on account of the income of the Company;

(b) for the payment of reasonable general and administrative costs and expenses;

(c) for the payment of management fees to Cerberus or Ampersand or their respective Affiliates pursuant to one or more management agreements;

(d) for the payment of any and all of its obligations owing to the lenders pursuant to the Senior Credit Agreement and the Second Lien Credit Agreement, as such Senior Credit Agreement or Second Lien Credit Agreement may be amended, extended, renewed, refinanced or replaced, provided that such payments may not be made to Talecris LLC or its Affiliates to the extent that the principal amount of Indebtedness then owed to Talecris LLC, incurred pursuant to any such amendment, extension, renewal, refinancing or replacement, exceeds the principal amount of the Indebtedness owed to Talecris LLC or its Affiliates pursuant to the Senior Credit Agreement or the Second Lien Credit Agreement prior to such amendment, extension, renewal, refinancing or replacement, as applicable, plus the amount of interest, fees, premiums and other expenses payable in connection with such amendment, extension, renewal, refinancing or replacement;

(e) to the extent permitted by Section 2.02(c);

(f) for the purchase of fractional shares arising out of stock dividends, splits or combinations or business combinations; or

(g) in an amount, together with the aggregate amount of all other Restricted Payments made by the Company after the Effective Date pursuant to this subsection (g), not to exceed at any time, without duplication, the lesser of (A) the amount permissible pursuant to the then existing terms of the Senior Credit Agreement and the Second Lien Credit Agreement and (B) the sum of:

(i) 25% of the aggregate net income of the Company and its Subsidiaries on a consolidated basis, determined in accordance with GAAP, for the period (taken as one accounting period) from the Effective Date to the end of the Company’s most recently ended fiscal quarter for which internal financial statements are available at the time of such Restricted Payment, plus

(ii) 100% of the aggregate Net Proceeds received by the Company after the Effective Date from the issuance or sale of any Equity Interests of the Company or any Indebtedness or other securities of the Company convertible into or exercisable or exchangeable for Equity Interests of the Company, but only to the extent that such Indebtedness or securities have been so converted or exercised or exchanged.

Notwithstanding the foregoing, this Section 2.09 shall not prohibit or prevent any Restricted Payment at any time during which the Company has on deposit with a financial institution of recognized international standing acceptable to the Bayer Parties or their permitted transferees hereunder, as trust funds for the benefit of the Bayer Parties or their permitted transferees hereunder, cash in an amount equal to the sum of (i) the Put Price, plus interest accrued thereon to the date of the intended Restricted Payment, and (ii) the maximum Liquidation Value (as defined in the Junior Preferred Stock Designations) of the Junior Preferred Stock determined as if all remaining Annual Achievements in future Sales Target Years were achieved, plus dividends accrued thereon to the fixed Redemption Date, under such terms and conditions that ensure that the payment of the funds as provided hereunder to the Bayer Parties or their permitted transferees hereunder shall be bankruptcy proof.

Any dividend permitted in accordance with this Section 2.09 at the time declared shall not be prohibited when made, if within 30 days after such declaration.

For the avoidance of doubt, this Section 2.09 shall not override the separate application of any other provision of this Agreement, including without limitation Sections 2.01, 2.02 and 2.06 hereof, or of the Junior Preferred Stock Designations, including without limitation Sections 6 and 11 thereof.

SECTION 2.10 Board of Directors.

(a) At each annual or special stockholders meeting called for the election of directors, and whenever the stockholders of the Company act by written consent with respect to the election of directors, each Stockholder agrees to vote or otherwise give such Stockholder’s consent in respect of all shares of the Voting Stock of the Company owned by such Stockholder (whether now owned or hereafter acquired), and take all other appropriate action, and the Company shall take all necessary and desirable actions, to cause:

(i) the Bylaws of the Company to provide that the authorized number of directors on the board shall initially be seven, and thereafter such number, not fewer than five, as shall be designated by Cerberus Capital Management, L.P. (“Cerberus”) from time to time;

(ii) the election to the board of:

(A) two representatives designated by Ampersand 2001 Limited Partnership (“Ampersand”); and

(B) representatives designated by Cerberus to fill any seat on such board not filled by the representatives designated by Ampersand;

all of which persons shall hold office subject to their earlier removal in accordance with clause (iii) below, the Bylaws of the Company and applicable corporate law, until their respective successors shall have been elected and shall have qualified;

(iii) the removal from the board of any director elected in accordance with clause (ii) above, with or without cause, upon the written request of the Person that designated such director for appointment; and

(iv) upon any vacancy in the board as a result of any individual designated as provided in clause (ii) above ceasing to be a member of the board, whether by resignation or otherwise, the election to the board to fill such vacancy, as promptly as possible, of an individual designated by the Person that designated such first-mentioned individual for appointment.

(b) Cerberus and Ampersand each is intended to be, and is hereby constituted, a third party beneficiary of this Section 2.10, with full rights to enforce this Section 2.10 as though each was a party to this Agreement. The parties hereto acknowledge that Cerberus and Ampersand are receiving the rights set forth in Section 2.10(a) as a result of their ownership interest in Talecris LLC.

ARTICLE III

RESTRICTIONS ON TRANSFER

SECTION 3.01 General Restriction.

(a) No Bayer Party, without the prior written consent of the Company, which may be given or withheld in its absolute discretion, may Transfer or permit the Transfer of any Common Shares except as specifically provided below:

(i) At any time, a Bayer Party may Transfer any Common Shares to Permitted Transferees without complying with Sections 3.03 and 3.05 but subject to compliance with Section 3.06; provided, however, that no Bayer Party may Transfer any Common Shares to any Permitted Transferee if the purpose of such Transfer is to dispose of such Common Shares and if the value of such Common Shares at the time of such Transfer represents more than 20% of the net worth of such Permitted Transferee; provided, further, that if any such Permitted Transferee, subsequent to the time of Transfer, ceases to be a “Permitted Transferee” as defined herein, such event shall be deemed a Transfer of Common Shares subject to the provisions of Section 3.01(a), except if prior to such Permitted Transferee ceasing to be such, the Common Shares are transferred to a Permitted Transferee.

(ii) After the expiration of one year from the Effective Date until the third anniversary of the Effective Date, any Bayer Party may Transfer any Common

Shares to any Person that is not a Competitor, subject to compliance with Sections 3.05 and 3.06.

(iii) After the third anniversary of the Effective Date, any Bayer Party may Transfer any Common Shares to any Person, subject to compliance with Sections 3.05 and 3.06.

(iv) At any time, a Bayer Party may Transfer any Common Shares as may be permitted by Section 3.03 or required by Section 2.04 or Section 3.04.

(v) Beginning 180 days after the consummation of an IPO (or such shorter period after the consummation of an IPO as may be permitted by the managing underwriters of the IPO), a Bayer Party may Transfer any Common Shares without restriction, except as required by law.

(b) For the avoidance of doubt, there are no restrictions on Transfer of the Junior Preferred Stock, except as required by law, and any transferee of Junior Preferred Stock shall succeed to the rights and obligations of any Bayer Party with respect thereto set forth in this Agreement.

SECTION 3.02 Legends.

The Company shall affix to each certificate evidencing Shares a legend in substantially the following form:

“THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO REGISTRATION OF TRANSFER OF SUCH SECURITIES WILL BE MADE ON THE BOOKS OF THE ISSUER UNLESS SUCH TRANSFER IS MADE IN CONNECTION WITH AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR PURSUANT TO AN EXEMPTION OR EXCLUSION FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT.

THE SECURITIES EVIDENCED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER AS SET FORTH IN A STOCKHOLDERS AGREEMENT, DATED AS OF MARCH 31, 2005, AS IT MAY THEREAFTER BE AMENDED, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL CORPORATE OFFICES OF THE ISSUER (THE “STOCKHOLDERS AGREEMENT”). NO REGISTRATION OF TRANSFER OF SUCH SECURITIES WILL BE MADE ON THE BOOKS OF THE ISSUER UNLESS AND UNTIL SUCH RESTRICTIONS SHALL HAVE BEEN COMPLIED WITH.

THE HOLDER OF THE SECURITIES EVIDENCED BY THIS CERTIFICATE IS ENTITLED TO CERTAIN RIGHTS AND SUBJECT TO CERTAIN OBLIGATIONS AS SET FORTH IN THE AFOREMENTIONED STOCKHOLDERS AGREEMENT.”

SECTION 3.03 Tag-Along Rights.

(a) Subject to Section 3.03(f), if at any time Talecris LLC proposes to Sell (a “Tag-Along Transfer”), in a single transaction or series of transactions, all or any portion of its Shares held by it (the “Tag-Along Shares”) to a Third Party, each Bayer Party shall have the opportunity to Sell its Pro Rata Share of the Tag-Along Shares (“Tag-Along Right”). Talecris LLC shall provide written notice (the “Tag-Along Offer Notice”) of such Tag-Along Transfer not later than 30 days prior to the consummation of the Tag-Along Transfer to the Bayer Parties disclosing (i) the identity of the proposed purchaser, (ii) the number of Tag-Along Shares, (iii) the price at which the Tag-Along Shares are proposed to be Sold (the “Tag-Along Offer Price”), and (iv) all other material terms and conditions of the Tag-Along Transfer. Talecris LLC agrees to use commercially reasonable efforts to obtain the agreement of the prospective purchaser to the participation of the Bayer Parties in the contemplated Tag-Along Transfer, and agrees not to Transfer any shares to a prospective purchaser that declines to allow the participation of the Bayer Parties in accordance with this Section 3.03.

(b) If any Bayer Party desires to exercise the Tag-Along Right, it shall, prior to the expiration of 20 days after the Tag-Along Offer Notice is provided (the “Notice Period”), provide Talecris LLC with a written notice specifying the number of Common Shares which it has an interest in Selling pursuant to the Tag-Along Transfer (a “Notice of Interest”). The Bayer Party exercising the Tag-Along Right may specify in the Notice of Interest a number of Common Shares that is greater than its Pro Rata Share (as defined below); provided, however, the Company, in its absolute discretion, may limit the number of Common Shares to be Sold by any Bayer Party pursuant to this Section 3.03 to its Pro Rata Share. Delivery of a Notice of Interest shall constitute an irrevocable election by such Bayer Party to Sell the number of Common Shares specified in such Notice of Interest pursuant to the terms of the Tag-Along Transfer at a price equal to the Tag-Along Offer Price. If any Bayer Party delivers a Notice of Interest, it agrees that it will deliver to the closing of the Tag-Along Transfer certificates evidencing the Common Shares to be Sold by it in the Tag-Along Transfer duly endorsed in blank or accompanied by written instruments of transfer in form reasonably satisfactory to Talecris LLC executed by such Bayer Party and will execute such other documents containing such terms and conditions (including customary representations and warranties that relate specifically to its Common Shares being Sold) that Talecris LLC may reasonably request in order to consummate the Tag-Along Transfer at the time specified by Talecris LLC. In the event that any Bayer Party fails to deliver any of the foregoing on or before the closing, then such Bayer Party will be deemed to have irrevocably waived all of its rights under this Section 3.03 with respect to any future Tag-Along Transfers. The “Pro Rata Share” which a Bayer Party shall be entitled to Sell shall be a number of Common Shares equal to the product obtained by multiplying (x) the total number of Common Shares owned by such Bayer Party by (y) a fraction, the numerator of which shall be the number of Fully Diluted Common Shares into which Shares proposed to be Sold by Talecris LLC are convertible, exercisable or exchangeable and the denominator shall be the total number of Shares owned by Talecris LLC, assuming the conversion, exercise or exchange of all Equity Interests of the Company owned by such Stockholder; provided, however, that if the proposed Third Party purchaser in the Tag-Along Transfer is not willing to purchase the total of the Tag-Along Shares to be Sold by Talecris LLC and the Pro Rata Share of each Bayer Party at the same per unit Tag-Along Offer Price and on the same terms and conditions contained in the offer for the Tag-Along Transfer, then the number of the Tag-Along Shares to be Sold by

Talecris LLC and the Pro Rata Share of each Bayer Party shall be cut back pro rata (i.e., the number of Shares that each of Talecris LLC and the Bayer Parties may Sell shall bear the same percentage to total number of Shares held by each of them, assuming the conversion, exercise or exchange of all Equity Interests of the Company owned by such Stockholder).

(c) On the date of the consummation of the Tag-Along Transfer, Talecris LLC shall remit or cause to be remitted to the Bayer Parties participating in the Tag-Along Transfer the total sales price of the Common Shares sold by such Bayer Parties, as applicable, less a pro rata portion of the documented and reasonable out-of-pocket expenses (including, without limitation, reasonable legal fees and expenses) incurred by Talecris LLC in connection with such Tag-Along Transfer.

(d) If, at the end of a Notice Period, any of the Bayer Parties shall not have exercised its Tag-Along Right, each such Bayer Party will be deemed to have waived all of its rights under this Section 3.03 with respect to the particular Tag-Along Transfer described in the applicable Tag-Along Offer Notice.

(e) Section 3.03(a) shall not apply to any Sale by Talecris LLC (i) as part of a Public Offering by the Company in which the Bayer Parties have been offered the right to participate on a pro rata basis, (ii) pursuant to an Approved Sale in which the Bayer Parties have been offered the right to participate on a pro rata basis, (iii) to its Affiliates provided that any such Affiliate agrees in writing to be bound by the provisions of this Agreement affecting the Equity Interests so transferred or (iv) of less than 10% of the Shares beneficially owned by Talecris LLC as of the date hereof.

(f) Notwithstanding anything to the contrary in Section 3.03, no Bayer Party may elect to participate in a Tag-Along Transfer during the period after the Company has given a Notice of Election pursuant to Section 2.01(b) and the Board of Directors of the Company has determined that the Company has sufficient funds available to pay the Call Price, and has reserved sufficient funds therefor, and before the earlier of the payment of the Call Price and withdrawal by the Company of the Notice of Election.

(g) This Section 3.03 shall terminate immediately prior to the consummation of an IPO.

SECTION 3.04 Drag-Along Right.

(a) In the event that Talecris LLC proposes to Sell (the “Drag-Along Sale”) all or any portion of the Shares held by it to a Third Party in a single transaction or series of related transactions that would result in such Third Party and its Affiliates becoming the beneficial owner, directly or indirectly, of 50% or more of the Fully Diluted Common Shares of the Company, Talecris LLC may require each Bayer Party to participate in such Drag-Along Sale and Sell the same percentage of its Common Shares, as the Fully Diluted Common Shares that would be Sold by Talecris LLC, assuming the conversion, exercise or exchange of all Equity Interests of the Company, represent to the total number of Fully Diluted Common Shares that would be held by Talecris LLC, assuming the conversion, exercise or exchange of all Equity

Interests of the Company, on the same terms and conditions and at the same time or times as applicable to Talecris LLC.

(b) Talecris LLC shall, promptly upon determining the terms of the Drag-Along Sale, deliver to each Bayer Party written notice (the “Drag-Along Notice”) specifying the material terms of the Drag-Along Sale, including the identity of the purchaser to which the Drag-Along Sale is proposed to be made, the terms per Fully Diluted Common Share of such Sale and the costs expected to be incurred by Talecris LLC in connection with such Sale. In connection with any such Sale, each Bayer Party will agree (i) to make or agree to any customary representations, covenants, indemnities and agreements as Talecris LLC so long as they are made severally and not jointly and the liabilities thereunder are borne on a pro rata basis based on the numbers of Fully Diluted Common Shares into which Shares sold by each Stockholder are convertible, exercisable or exchangeable and (ii) to pay their proportionate share of the reasonable and documented costs (including, without limitation, reasonable legal fees and expenses) incurred by each of Talecris LLC and the Bayer Parties in connection with such Drag-Along Sale to the extent not paid or reimbursed by the Company or the Third Party.

(c) Each Bayer Party agrees that it will deliver at the closing of the Drag-Along Sale certificates evidencing the Common Shares to be sold by such Bayer Party in the Drag-Along Sale duly endorsed in blank or accompanied by written instruments of transfer in form reasonably satisfactory to Talecris LLC executed by such Bayer Party, and each Bayer Party shall execute such other documents of transfer that Talecris LLC may reasonably request in order to consummate the Drag-Along Sale at the time specified by Talecris LLC.

(d) On the date of the consummation of the Drag-Along Sale, Talecris LLC shall remit or cause to be remitted to each Bayer Party its portion of the consideration for the Common Shares sold pursuant thereto less its proportionate share of the reasonable and documented costs (including, without limitation, reasonable legal fees and expenses) incurred in connection with such Drag-Along Sale, including costs incurred by the Bayer Parties, to the extent not paid or reimbursed by the Company or the Third Party.

(e) Anything herein to the contrary notwithstanding, Talecris LLC shall have no obligation to any Bayer Party to Sell any Shares pursuant to this Section 3.04 as a result of any decision by Talecris LLC not to accept or consummate any Drag-Along Sale (it being understood that any and all such decisions shall be made by Talecris LLC in its sole discretion). The Bayer Parties shall not be entitled to make any Sale of Common Shares directly to any Third Party pursuant to a Drag-Along Sale (it being understood that all such Sales shall be made only on the terms and pursuant to the procedures set forth in this Section 3.04).

(f) Notwithstanding anything to the contrary in Section 3.04, Talecris LLC may not require any Bayer Party to participate in any Drag-Along Sale during the period after Bayer has given a Notice of Election pursuant to Section 2.01(a) and before the earlier of the payment of the Put Price and withdrawal by Bayer of the Notice of Election.

(g) This Section 3.04 shall terminate immediately prior to the consummation of an IPO.

SECTION 3.05 Right of First Offer upon Sales of Shares.

(a) If at any time any Bayer Party desires to Sell all or any part of its Common Shares to any Person pursuant to Section 3.01(a)(ii) or Section 3.01(a)(iii) (other than as part of a Public Offering by the Company), such Bayer Party (the “Selling Party”) shall give written notice to the Company and Talecris LLC stating the Selling Party’s bona fide intention to make such Sale, the number of Common Shares proposed to be Sold and the price and other terms on which such Selling Party proposes to make such Sale. For purposes of this Agreement, any notice stating a Selling Party’s bona fide intention to Sell Common Shares shall hereinafter be called a “Selling Party’s Notice”; the Common Shares covered by any Selling Party’s Notice shall hereinafter be called the “Offered Shares”; and the price and other terms on which the Selling Party proposes to make such Sale shall hereinafter be called the “Offer Terms”. Each Selling Party’s Notice shall constitute an irrevocable offer by the Selling Party to Sell the Offered Shares on the Offer Terms to the Company and/or Talecris LLC.

(b) The Company and Talecris LLC, acting jointly, may, within 30 days following the date of their receipt of the Selling Party’s Notice (the “Offer Period”), give the Selling Party a notice (the “Joint Notice”) that states (i) the maximum amount of such Offered Shares that the Company and/or Talecris LLC elects to purchase; (ii) that the election made in such notice is irrevocable; and (iii) that either the Company or Talecris LLC, or the Company and Talecris LLC together, irrevocably commit to purchase all, and not less than all, of the Offered Shares on the Offer Terms. In determining the allocation of the Offered Shares between the Company and Talecris LLC, the Company shall have the right to elect to purchase any amount of the Offered Shares up to the maximum amount, and Talecris LLC shall have the right to elect to purchase the remainder, if any, of the Offered Shares that the Company does not elect to purchase.

(c) The closing of any purchase and Sale to the Company and/or Talecris LLC pursuant to this Section 3.05 shall take place on such date as the applicable parties shall mutually agree, but not later than 45 days following the expiration of the Offer Period.

(d) Upon expiration of the Offer Period, without the Offered Shares being accepted in full by either or both Talecris LLC and the Company in accordance with this Section 3.05, the Selling Party shall be free, for 180 days following the expiration of the Offer Period, to Sell the Offered Shares to any Third Party pursuant to a bona fide offer in writing upon such terms and conditions as the Selling Party may desire; provided, however, that the Offered Shares may be Sold to the Third Party only if the per Offered Share purchase price actually and irrevocably paid by such Third Party is equal to or greater than 95% of the proposed purchase price contained in the Offer Terms.

(e) Upon the request of the Company or Talecris LLC, the Selling Party shall provide to Talecris LLC with documentation in a form reasonably satisfactory to Talecris LLC that demonstrates compliance with Section 3.05(d).

(f) If the Selling Party shall not have Sold all of the Offered Shares prior to the expiration of the 180-day period following the Offer Period, then the commitments set forth in the applicable Selling Party’s Notice and the Joint Notice shall terminate, the provisions of

this Section 3.05 shall again apply, and such Selling Party shall not effect a Sale or offer to effect a Sale of any of its Common Shares not so Sold during such period without again complying with this Section 3.05.

(g) If, pursuant to the Offer Terms, a Selling Party proposes to sell Offered Shares in exchange for consideration other than cash and the Company and/or Talecris LLC deliver a Joint Notice and commit to purchase the Offered Shares, the parties shall engage an investment banking firm of national reputation mutually acceptable to the parties (the “Valuation Firm”) to value such non-cash consideration for purposes of determining the price in cash that the Company and/or Talecris LLC shall pay such Selling Party for the Offered Shares. The Selling Party shall, and if applicable shall cause the proposed purchaser of the Offered Shares to, make available to the Valuation Firm all information reasonably necessary to permit the Valuation Firm to value such non-cash consideration. The parties will instruct the Valuation Firm to use its best efforts to complete the valuation as promptly as practicable. The determination of the Valuation Firm shall be binding on the parties. The Selling Party, on the one hand, and the Company and Talecris LLC, on the other hand, shall share equally in the costs, expenses and fees of the Valuation Firm.

(h) This Section 3.05 shall terminate immediately prior to the consummation of an IPO.

SECTION 3.06 Agreement to be Bound.

No Sale of Shares by any Bayer Party, other than pursuant to Section 3.01(a)(v), Section 3.03 and Section 3.04, shall be effective unless the transferee shall have executed and delivered to the Company, as a condition precedent to such Sale, an agreement in form and substance reasonably satisfactory to the Company confirming that such transferee agrees to be bound by the terms of this Agreement, including Sections 3.01, 3.03, 3.04, 3.05, 3.07 and 5.04. Any such transferee shall succeed to the rights of any Bayer Party hereunder.

SECTION 3.07 Compliance with Securities Laws.

No Stockholder shall Sell any securities of the Company, and the Company shall not transfer on its books any securities, unless (a) the Sale is pursuant to an effective Registration Statement under the Securities Act and under any applicable state securities or blue sky laws or (b) such Stockholder shall have furnished the Company with an opinion of counsel, to the extent reasonably required by the transfer agent of the Company, to the effect that no such registration is required because of the availability of an exemption from registration under the Securities Act and under applicable state securities or blue sky laws. The Company shall not require an opinion of counsel for Sales by Stockholders in compliance with Rule 144 under the Securities Act or any successor rule. The Company acknowledges and agrees that a Sale made in compliance with the Securities Act and applicable state securities and blue sky laws to an entity owning, directly or indirectly, all the common equity of such Stockholder or any wholly owned direct or indirect subsidiary of such parent entity shall be deemed to be in compliance with this Agreement and no such opinion of counsel shall be required.

ARTICLE IV

REGISTRATION RIGHTS

SECTION 4.01 Demand Registration Rights.

(a) Commencing twelve months following the consummation of an IPO but not within 180 days after the consummation of any Public Offering, the Bayer Parties collectively shall have the one-time right, and Talecris LLC shall have an unlimited number of rights, to require the Company to file a Registration Statement under the Securities Act, covering all or any part of their respective Registrable Securities, by delivering a written notice therefor to the Company specifying the number of Registrable Securities to be included in such registration and the intended method of distribution thereof. Such request pursuant to this Section 4.01 is referred to herein as the “Demand Registration Request,” the registration so requested is referred to herein as the “Demand Registration” and the party making such request is the “Demanding Party.” As promptly as practicable, but no later than ten Business Days after receipt of the Demand Registration Request, the Company shall give written notice (the “Demand Exercise Notice”) of such Demand Registration Request to all Stockholders party hereto and any other Stockholders with piggyback registration rights pursuant to Section 4.02 hereof or any similar agreement.

(b) The Company shall include in the Demand Registration the Registrable Securities of any Stockholders parties hereto or party to any other agreement providing similar piggyback registration rights that shall have made a written request to the Company for inclusion thereof in such registration (which request shall specify the maximum number of Registrable Securities intended to be disposed of by such other Stockholders) within 30 days after the receipt of the Demand Exercise Notice.

(c) The Company shall use its reasonable best efforts to (i) effect the registration under the Securities Act (including by means of a shelf registration pursuant to Rule 415 under the Securities Act if so requested by the Demanding Party and the Company is then eligible to effect such a registration) of the Registrable Securities which the Company has been so requested to register by the Demanding Party and other Stockholders (to the extent permitted to be included in accordance with the terms hereof), for distribution, in accordance with such intended method of distribution and (ii) if requested by the Demanding Party, obtain acceleration of the effective date of the Registration Statement relating to such registration.

(d) A registration requested pursuant to this Section 4.01 will not be deemed to have been effected unless the relevant Registration Statement has become effective; provided that if, after it has become effective, the offering of Registrable Securities pursuant to such registration is subject to any stop order, injunction or other order or requirement of the Commission or other Governmental Authority for an aggregate of more than 30 days in the 210 days following the date of effectiveness, such registration will be deemed not to have been effected.

(e) If a requested registration pursuant to this Section 4.01 involves an underwritten offering, the Demanding Party shall have the right to select an investment banker or

bankers of nationally recognized standing to administer the offering; provided, however, that such investment banker or bankers shall be reasonably satisfactory to the Company. The Company shall notify the Demanding Party if the Company objects to any investment banker or manager selected by the Demanding Party pursuant to this Section 4.01(e) within ten Business Days after the Demanding Party has notified the Company of such selection.

(f) Notwithstanding anything to the contrary in this Section 4.01:

(i) If the managing underwriter of any underwritten Public Offering shall advise the Stockholders participating in a Demand Registration that the Registrable Securities covered by the Registration Statement cannot be sold in such offering within a price range acceptable to the Demanding Party, then the Demanding Party shall have the right to notify the Company that it has determined that the Registration Statement be abandoned or withdrawn, in which event the Company shall abandon or withdraw such Registration Statement.

(ii) If the Board of Directors of the Company determines in good faith that a Disadvantageous Condition exists, the Company shall, notwithstanding any other provision of this Article IV, be entitled, upon the giving of a written notice (a “Delay Notice”) to such effect to each holder of Registrable Securities included or to be included in such Registration Statement, to delay the filing of such Registration Statement until, in the judgment of the Board of Directors of the Company, such Disadvantageous Condition no longer exists (notice of which the Company shall promptly deliver to the holders of the Registrable Securities with respect to which any such Registration Statement was to have been filed); provided, however, that such delay shall not exceed a period of 180 days from the date the Demand Registration Request is received by the Company; provided, further, that the Company may not utilize this right more than once in any twelve-month period.

(iii) Notwithstanding the foregoing provisions of this Section 4.01(f), no Registration Statement filed and subsequently withdrawn pursuant to clause (i) or by reason of any existing or anticipated Disadvantageous Condition as provided in clause (ii) shall count as the one Registration Statement referred to in the limitation to Bayer Parties in Section 4.01(h)(i).

(iv) If, as a result of Section 4.01(g), fewer than all of the Registrable Securities of the Bayer Parties as to which the Bayer Parties demanded registration have been registered, then the Bayer Parties shall be entitled to one additional demand registration right.

(g) In connection with any Demand Registration Request, if the managing underwriter shall advise the Company that, in its view, the number of securities (including all Registrable Securities) that the Company and holders of Registrable Securities intend to include in such registration exceeds the largest number of securities which can be sold in such offering at a price reasonably acceptable to the Demanding Party (the “Demand Registration Maximum Offering Size”), the Company will include first in such registration, Registrable Securities in the following priority, up to the Demand Registration Maximum Offering Size:

(i) first, the Registrable Securities that the Demanding Party proposes to include in such registration or, in the case of a demand by Talecris LLC, the Registrable Securities of Talecris LLC and the Bayer Parties pro rata on the basis of the relative number of Registrable Securities each such holder has requested to be included in such registration;

(ii) second, the Registrable Securities that the Company proposes to include in such registration; and

(iii) third, the Registrable Securities that other Stockholders propose to include in such registration.

(h) In addition, the Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to this Section 4.01 with respect to any Demanding Party, during the period starting with the date 30 days prior to the Company’s good faith estimate of the date of filing of, and ending on a date 180 days after the effective date of, a registration subject to Section 4.02 hereof.

SECTION 4.02 Piggyback Registration Rights.

(a) At any time commencing six months following an IPO, if the Company proposes to register any shares of Common Stock under the Securities Act on a form and in a manner that would permit registration of Registrable Securities for sale to the public under the Securities Act, each holder of Registrable Securities will have the right to include its Registrable Securities in such registration in accordance with this Section 4.02 and the Company will give prompt written notice to all holders of Registrable Securities of its intention to do so, describing the number of shares to be registered for sale and specifying the form and manner and the other relevant facts involved in such proposed registration (including, without limitation, whether or not such registration will be in connection with an underwritten offering of its Common Stock and, if so, the identity of the managing underwriter and whether such offering will be pursuant to a “best efforts” or “firm commitment” underwriting). Upon the written request of any holder of Registrable Securities delivered to the Company within 30 days after such notice shall have been received by such holder (which request shall specify the maximum number of Registrable Securities intended to be disposed of by such holder and shall confirm that such holder will dispose of such Registrable Securities pursuant to the Company’s intended method of disposition), the Company will use its reasonable best efforts to effect the registration under the Securities Act of all Registrable Securities that the Company has been so requested to register by the holders of Registrable Securities, to the extent requisite to permit the disposition (in accordance with the Company’s intended method of disposition) of the Registrable Securities so to be registered; provided, however, that:

(i) if such registration involves an underwritten offering, all holders of Registrable Securities requesting to be included in such registration must sell their Registrable Securities to the underwriters selected by the Company on the same terms and conditions as apply to the Company;

(ii) if, at any time after giving such written notice of its intention to register any of such Registrable Securities for sale, and prior to the effective date of the Registration Statement filed in connection with such registration, the Company shall determine for any reason to withdraw such Registration Statement, the Company may, at its election, give written notice of such determination to each holder of Registrable Securities that has requested to register Registrable Securities and thereupon the Company shall be relieved of its obligation to register any Registrable Securities in connection with such registration; provided, however, that all Registration Expenses of such withdrawn registration shall be borne by the Company in accordance with Section 4.04 hereof; and

(iii) the Company shall have no obligation to provide piggy back registration rights pursuant to this Section 4.02 during the period starting with the date 30 days prior to the Company’s good faith estimate of the date of filing of, and ending on a date 180 days after the effective date of, a registration subject to Section 4.01 hereof; provided, however, that the Company is using its reasonable best efforts to cause such registration statement to become effective and all Registrable Securities requested by the holders to be registered shall have been so registered.

(b) In connection with any Public Offering with respect to which holders of Registrable Securities shall have requested registration pursuant to this Section 4.02, if the managing underwriter shall advise the Company that, in its view, the number of securities (including all Registrable Securities) that the Company and holders of Registrable Securities intend to include in such registration exceeds the largest number of securities which can be sold without having an adverse effect on such offering, including the price at which such securities can be sold (the “Piggyback Registration Maximum Offering Size”), the Company will include in such registration, in the following priority, up to the Piggyback Registration Maximum Offering Size:

(i) first, all the securities that the Company proposes to include in such registration; and

(ii) second, all securities requested to be included in such registration by all other holders of securities which are entitled to incidental registration rights (allocated, if necessary for the offering not to exceed the Piggyback Registration Maximum Offering Size, pro rata among such holders on the basis of the relative number of securities each such holder shall have requested to be included in such registration).

(c) If a Stockholder decides not to include all of its Registrable Securities in any Registration Statement thereafter filed by the Company, such Stockholder shall nevertheless continue to have the right to include any Registrable Securities in any subsequent Registration Statement or Registration Statements as may be filed by the Company with respect to offerings of securities, all upon the terms and conditions set forth herein.

SECTION 4.03 Registration on Form S-3.

After the date on which the Company or Parent has effected an IPO, if the Company is entitled to use Form S-3 (or any successor form to Form S-3 regardless of its designation) for a public offering of securities, any Bayer Party may require, upon written notice specifying that such notice is being made pursuant to this Section 4.03, that the Company file a Registration Statement on Form S-3 for a public offering of securities having an aggregate value of at least $5 million; provided, however, that the Company will not be obligated to effect more than one Form S-3 Registration Statement in any twelve-month period. Any such offering shall not be required to be underwritten.

SECTION 4.04 Registration Expenses.

The Company shall pay all Registration Expenses in connection with the registration of Registrable Securities effected by it pursuant to this Article IV. “Registration Expenses” means all expenses incident to the Company’s performance of or compliance with Article IV, including, without limitation, all registration, filing and qualification fees (including filing fees with respect to the NASD), all fees and expenses of complying with state securities or “blue sky” laws (including reasonable fees and disbursements of underwriters’ counsel in connection with any “blue sky” memorandum or survey), all printing expenses, all listing fees, all registrars’ and transfer agents’ fees, the fees and disbursements of counsel for the Company and of its independent certified public accountants, including the expenses of any special audits and/or “comfort” letters required by or incident to such performance and compliance, but excluding underwriting discounts and commissions, applicable transfer taxes, if any, and the fees and disbursements of the attorneys-in-fact, the custodian and counsel for the sellers of Registrable Securities.

SECTION 4.05 Registration Procedures.

(a) If and whenever the Company is required to effect the registration of any Registrable Securities under the Securities Act as provided in this Article IV, the Company will:

(i) promptly prepare and file with the Commission a Registration Statement with respect to such Registrable Securities and use its reasonable best efforts to cause such Registration Statement to become effective as soon as reasonably practicable thereafter;

(ii) prepare and file with the Commission such amendments (including post-effective amendments) and supplements to such Registration Statement and the Prospectus used in connection therewith as may be necessary to keep such Registration Statement effective and to comply with the provisions of the Securities Act with respect to the disposition of all Registrable Securities and other securities covered by such Registration Statement until the earlier of (a) such time as all such Registrable Securities and other securities have been disposed of in accordance with the intended methods of disposition by the seller or sellers thereof set forth in such Registration Statement and (b) the expiration of six months from the date such Registration Statement first becomes effective;

(iii) furnish to each seller of such Registrable Securities such number of conformed copies of such Registration Statement and of each such amendment and supplement thereto (in each case including all exhibits), such number of copies of the Prospectus included in such Registration Statement, in conformity with the requirements of the Securities Act, such documents incorporated by reference in such Registration Statement or Prospectus and such other documents as such seller may reasonably request in order to facilitate the Sale of such Registrable Securities;

(iv) register or qualify all Registrable Securities and other securities covered by such Registration Statement under such other securities or “blue sky” laws of such jurisdictions as each seller shall reasonably request, and do any and all other acts and things that may be necessary to enable such seller to consummate the disposition in such jurisdictions of its Registrable Securities covered by such Registration Statement, except that the Company shall not for any such purpose be required to qualify generally to do business as a foreign corporation in any jurisdiction wherein it is not so qualified, to subject itself to taxation in respect of doing business in any such jurisdiction or to consent to general service of process in any such jurisdiction;

(v) furnish to each seller of Registrable Securities, on the date that the Registrable Securities are delivered to the underwriters for sale in connection with a Public Offering, or, if such registration does not involve a Public Offering on the date that the Registration Statement with respect to such Registrable Securities becomes effective, (a) an opinion, dated such date, of the counsel representing the Company for the purpose of such registration, in form and substance as is customarily given to underwriters in a Public Offering, addressed to the underwriters, if any, or if there are no such underwriters, to the sellers of Registrable Securities in such registration and (b) a “comfort” letter dated such date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in a Public Offering, addressed to the underwriters, if any, or if there are no such underwriters, to the sellers of Registrable Securities;

(vi) promptly notify each seller of Registrable Securities covered by such Registration Statement at any time when a Prospectus relating thereto is required to be delivered under the Securities Act, of the happening of any event as a result of which the Prospectus included in such Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing and if it is necessary to amend or supplement such Prospectus to comply with applicable law, and at the request of any such seller prepare and furnish to such seller a reasonable number of copies of a supplement to or an amendment of such Prospectus as may be necessary so that, as thereafter delivered to the purchasers of such Registrable Securities, such Prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing and shall otherwise comply in all material respects with applicable law;

(vii) comply with all applicable rules and regulations of the Commission, and make available to its security holders, as soon as reasonably practicable, an earning statement covering a period of at least twelve months, beginning with the first month of the first fiscal quarter after the effective date of such Registration Statement, which earning statement shall satisfy the provisions of Section 11(a) of the Securities Act;

(viii) send appropriate officers of the Company to attend any “road shows” and analyst presentations and otherwise use commercially reasonable efforts to cooperate as requested by the underwriters or sellers of Registrable Securities in the offering, marketing or selling of the Registrable Securities;

(ix) cause all such Registrable Securities registered pursuant hereto to be listed on a securities exchange or quoted on any interdealer quotation system, if such listing or quotation is then permitted under the rules of such exchange or quotation system, and provide a transfer agent, registrar and CUSIP number for such Registrable Securities no later than the effective date of such Registration Statement; and

(x) issue to any underwriter to which any holder of Registrable Securities may sell such Registrable Securities in connection with any such registration (and to any direct or indirect transferee of any such underwriter) certificates evidencing shares of Common Stock without the legends described in Section 3.02.

The Company may require each seller of Registrable Securities as to which any registration is being effected to furnish the Company with such information regarding such seller and the distribution of such Registrable Securities as the Company may from time to time reasonably request in writing and as shall be required by applicable law or by the Commission in connection therewith.

(b) If requested by the underwriters for any Public Offering of Registrable Securities on behalf of a holder or holders of Registrable Securities pursuant to a registration requested under Section 4.01 or 4.02 hereof, the Company and the Stockholders will enter into and perform its respective obligations under an underwriting agreement with such underwriters for such offering, such agreement to contain such representations and warranties by the Company and the Stockholders and such other terms and conditions as are customarily contained in underwriting agreements with respect to secondary distributions, including, without limitation, indemnities to the effect and to the extent provided in Sections 4.07 and 4.08 hereof.

(c) If any registration pursuant to Section 4.01 or 4.02 hereof shall be in connection with an underwritten Public Offering, each Stockholder agrees, if so required by the managing underwriter(s), not to effect any public sale or distribution (including any sale pursuant to Rule 144) of Registrable Securities (other than as part of such underwritten Public Offering) within seven days prior to the anticipated effective date of the Registration Statement with respect to such underwritten Public Offering or 90 days after the effective date of such Registration Statement; provided, however, that the 90 day period referred to in this Section 4.05(c) may be extended to up to 180 days upon the managing underwriter’s or underwriters’ reasonable request.

(d) The Company agrees, if so required by the managing underwriter(s) in connection with an underwritten Public Offering of Registrable Securities pursuant to Section 4.01 or 4.02, not to effect any public sale or distribution of any of its Equity Interests (other than as part of such underwritten Public Offering) within seven days prior to the anticipated effective date of the Registration Statement with respect to such underwritten Public Offering or 90 days after the effective date of such Registration Statement, except in connection with an Employee Plan registered on Form S-8 or an acquisition, merger or exchange offer; provided, however, that the 90-day period referred to in this Section 4.05(d) may be extended to up to 180 days upon the managing underwriter’s or underwriters’ reasonable request.

(e) It is understood that in any underwritten offering of Registrable Securities in addition to the shares (the “Initial Shares”) the underwriters have committed to purchase, the underwriting agreement may grant the underwriters an option to purchase a number of additional shares (the “Overallotment Option Shares”) equal to up to 15% of the Initial Shares (or such other maximum amount as the NASD may then permit), solely to cover over-allotments. Shares proposed to be sold by the Company and the holders of Registrable Securities shall be allocated between Initial Shares and Overallotment Option Shares as agreed or, in the absence of agreement, pursuant to Sections 4.01 or 4.02 hereof.

(f) No holder of Registrable Securities may participate in any Public Offering hereunder unless such holder (i) agrees to sell its Registrable Securities on the basis provided in any underwriting arrangements approved by the persons entitled hereunder to approve such arrangements and (ii) completes and executes all questionnaires, powers of attorney, indemnities, underwriting agreements and other documents reasonably required under the terms of such underwriting arrangements and this Article IV.

SECTION 4.06 Preparation; Reasonable Investigation.

In connection with the preparation and filing of each Registration Statement registering Registrable Securities under the Securities Act, the Company will give the holders of Registrable Securities on whose behalf such Registrable Securities are to be so registered and their underwriters, if any, and their respective counsel and accountants, the opportunity to participate in the preparation of such Registration Statement, each Prospectus included therein or filed with the Commission, and each amendment thereof or supplement thereto, and will give each of them such access to its books and records and such opportunities to discuss the business of the Company with its officers and the independent public accountants who have issued a report on its financial statements as shall be reasonably necessary, in the opinion of such holders and such underwriters or their respective counsel, to conduct a reasonable investigation within the meaning of the Securities Act.

SECTION 4.07 Indemnification.

(a) In the case of any Registration Statement filed under the Securities Act pursuant to Section 4.01 or Section 4.02, the Company will, and hereby does, indemnify and hold harmless, the seller of any Registrable Securities covered by such Registration Statement, its directors, officers and employees, each other Person who participates as an underwriter in the offering or sale of such Registrable Securities, each officer, director and employee of each such

underwriter, and each other Person, if any, who controls such seller, or each officer, director an employee of such seller, such underwriter, or each officer, director and employee of such underwriter, within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, against any losses, claims, damages, liabilities and expenses, joint or several, to which any such Person may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages, liabilities or expenses (or actions or proceedings in respect thereof) arise out of or are based upon (i) any untrue statement or alleged untrue statement of any material fact contained in any Registration Statement under which such securities were registered under the Securities Act, any Prospectus included therein, or any amendment or supplement thereto, or any document incorporated by reference therein, (ii) any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act or other federal or state law or any rule or regulation promulgated under the Securities Act, the Exchange Act or other federal or state law; and the Company will reimburse each such Person for any legal or any other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or expense; provided, however, that the Company shall not be liable in any such case to the extent that any such loss, claim, damage, liability or expense (or action or proceeding in respect thereof) arises out of or is based upon (x) an untrue statement or alleged untrue statement or omission or alleged omission made in such Registration Statement, any Prospectus included therein, or any amendment or supplement thereto, in reliance upon and in conformity with written information furnished to the Company for use in the preparation thereof by such seller, underwriter or non-selling controlling Person, as the case may be or (y) an untrue statement or alleged untrue statement or omission or alleged omission made in any preliminary Prospectus but notified to such seller and underwriter prior to any Sale of Registrable Securities and subsequently corrected by the Company in any final Prospectus made available to such seller or underwriter but which final Prospectus was not used by such seller or underwriter in the Sale of Registrable Securities that gave rise to such loss, claim, damage, liability or expense (or action or proceeding in respect thereof). Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Person and shall survive the transfer of such securities by such the seller.

(b) The Company may require, as a condition to including any Registrable Securities in any Registration Statement filed pursuant to this Article IV, that the Company shall have received an undertaking reasonably satisfactory to it from (i) the prospective seller of such Registrable Securities, to indemnify and hold harmless (in the same manner and to the same extent as set forth in Section 4.07(a) hereof, except that any such prospective seller shall not in any event be liable to the Company pursuant thereto for an amount in excess of the net proceeds of the sale of such prospective seller’s Registrable Securities so to be sold) the Company, each officer, director and employee of the Company, each underwriter of such securities, each officer, director and employee of each such underwriter and each other Person, if any, who controls the Company or any such underwriter or any officer, director or employee thereof within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act and (ii) each such underwriter of such securities, to indemnify and hold harmless (in the same manner and to the same extent as set forth in Section 4.07(a) hereof) the Company, each officer, director and employee of the Company, each prospective seller, each officer, director and employee of each prospective seller and each other Person, if any, who controls the Company or any such

prospective seller or any officer, director or employee thereof within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, with respect to any statement in or omission from such Registration Statement, any Prospectus included therein, or any amendment or supplement thereto, if such statement or omission was made in reliance upon and in conformity with written information furnished by such prospective seller or such underwriter, as the case may be, to the Company for use in the preparation of such Registration Statement, Prospectus, amendment or supplement; provided, however, that the indemnity agreement contained in this subsection 4.07(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or expense (or action or proceeding in respect thereof) if such settlement is effected without the consent of the indemnifying party; provided that in no event shall any indemnity under this subsection 4.07(b) exceed the net proceeds from the offering received by such indemnifying party. Such indemnity shall remain in full force and effect regardless of any investigation made by the indemnified party and shall survive the transfer of such securities by such seller.

(c) Promptly after receipt by an indemnified party of notice of the commencement of any action or proceeding (including any investigation by any Governmental Authority) involving a claim referred to in Section 4.07(a) or (b) hereof, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party, give written notice to the latter of the commencement of such action; provided, however, that the failure of any indemnified party to give notice as provided herein shall not relieve the indemnifying party of its obligations under the preceding provisions of this Section 4.07, except to the extent that the indemnifying party is actually prejudiced by such failure to give notice. In case any such action is brought against an indemnified party, unless in such indemnified party’s reasonable judgment a conflict of interest between such indemnified and indemnifying parties may exist in respect of such claim (in which case, the indemnifying party shall not be liable for the fees and expenses of more than one (1) counsel for all sellers of Registrable Securities, or more than one counsel for the underwriters in connection with any one (1) action or separate but similar or related actions), the indemnifying party will be entitled to participate in and to assume the defense thereof, jointly with any other indemnifying party similarly notified, to the extent that it may wish with counsel reasonably satisfactory to such indemnified party, and after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying party will not be liable to such indemnified party for any legal or other expenses subsequently incurred by the latter in connection with the defense thereof.

SECTION 4.08 Contribution.

(a) If the indemnification provided for in Section 4.07 is unavailable to the indemnified parties in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party shall contribute to the amounts paid or payable by such indemnified party as a result of such losses, claims, damages, liabilities or expenses (i) as between the Company and the holders of Registrable Securities covered by a Registration Statement, on the one hand, and the underwriters, on the other, in such proportion as is appropriate to reflect the relative benefits received by the Company and such holders, on the one hand, and the underwriters, on the other, from the offering of the Registrable Securities, or if such allocation is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits but also the relative fault of the Company and such holders, on the

one hand, and of the underwriters, on the other, in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations and (ii) as between the Company, on the one hand, and each holder of Registrable Securities covered by a Registration Statement, on the other, in such proportion as is appropriate to reflect the relative fault of the Company and of each such holder in connection with such statements or omissions, as well as any other relevant equitable considerations. The relative benefits received by the Company and such holders, on the one hand, and the underwriters, on the other, shall be deemed to be in the same proportion as the total proceeds from the offering (net of underwriting discounts and commissions but before deducting expenses) received by the Company and such holders bear to the total underwriting discounts and commissions received by the underwriters. The relative fault of the Company and such holders, on the one hand, and of the underwriters, on the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company and such holders or by the underwriters. The relative fault of the Company, on the one hand, and of each such holder, on the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact relates to information supplied by the Company or any such holder, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.

(b) The Company and the holders of Registrable Securities agree that it would not be just and equitable if contribution pursuant to this Section 4.08 were determined by pro rata allocation (even if the underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take account of the equitable considerations referred to in the next preceding paragraph. The amount paid or payable by an indemnified party as a result of the losses, claims, damages, liabilities or expenses referred to in the next preceding paragraph shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Section 4.08, no underwriter shall be required to contribute any amount in excess of the amount by which the total price at which the Registrable Securities underwritten by it and distributed to the public were offered to the public exceeds the amount of any damages that such underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission, and no holder of Registrable Securities shall be required to contribute any amount in excess of the amount by which the total price at which the Registrable Securities of such holder were offered to the public exceeds the amount of any damages that such holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The obligation of each holder of Registrable Securities to contribute pursuant to this Section 4.08 is several in the proportion that the proceeds of the offering received by such holder bears to the total proceeds of the offering received by all the holders and not joint.

SECTION 4.09 Nominees of Beneficial Owners.

In the event that any Registrable Securities are held by a nominee for the Beneficial Owner thereof, the Beneficial Owner thereof may, at its election, be treated as the holder of such Registrable Securities for purposes of any request or other action by any holder holders of Registrable Securities pursuant to this Agreement or any determination of any number or percentage of shares of Registrable Securities held by any holder or holders of Registrable Securities contemplated by this Agreement. If the Beneficial Owner of any Registrable Securities so elects, the Company may require assurances reasonably satisfactory to it of such Beneficial Owner’s ownership of such Registrable Securities.

ARTICLE V

INFORMATION RIGHTS

SECTION 5.01 Financial Information.

Subject to Section 5.04, the Company shall furnish to the Bayer Parties the following:

(a) within 90 days after the end of each of the Company’s fiscal years, balance sheets of the Company as of the end of such fiscal year and statements of income, changes in stockholders’ equity and cash flows of the Company for such fiscal year, audited by one of the “Big Four” U.S. accounting firms and a certificate of the chief financial officer of the Company as to the Company’s compliance with its covenants set forth in this Agreement; and

(b) within 45 days after the end of each of the Company’s fiscal quarters, unaudited balance sheets of the Company as of the end of such period and unaudited statements of income, changes in stockholders’ equity and cash flows from the beginning of the then current fiscal year and from the beginning of such fiscal quarter to the end of such period and a certificate of the chief financial officer of the Company as to the Company’s compliance with its covenants set forth in this Agreement.

SECTION 5.02 Requested Information.

In connection with any proposed Sale of Common Shares by any Bayer Party pursuant to Section 3.01(a)(ii) or Section 3.01(a)(iii) (other than as part of a Public Offering by the Company) or Sale of any shares of Junior Preferred Stock by Bayer, upon written request by such Bayer Party, the Company shall use its reasonable best efforts to cooperate with such Bayer Party, at such Bayer Party’s sole cost and expense, to provide information reasonably necessary to allow the potential purchaser to evaluate such Sale, subject to the prior execution by the potential purchaser of a customary confidentiality agreement reasonably satisfactory to the Company.

SECTION 5.03 Annual Sales Achievement Information.

So long as Bayer holds outstanding shares of Junior Preferred Stock, as promptly as practicable following (a) the end of each Sales Target Year, the Company shall provide Bayer

with a statement setting forth the Annual Net Sales for that year and calculations of the Annual Achievement and Annual Reduction for that year; (b) a Partial Sale, the Company shall provide Bayer with a statement setting forth the Special Liquidation Value, the Special Annual Achievements and the Deficit, along with the adjusted Annual Achievements for the remaining Sales Target Years or portions thereof; and (c) a Deemed Liquidation or Change of Control, the Company shall provide Bayer with a statement setting forth the Deemed Liquidation Value and the Deemed Annual Achievements (clause (a) through (c) collectively, the “Statement of Sales”). Upon Bayer’s prior written request, the Company shall make available, at reasonable times and places, to Bayer and, if Bayer so elects, Bayer’s independent certified public accountants, at no expense, such books and records as are reasonably necessary to review and verify the amounts set forth in the Statement of Sales and causes of any Annual Reductions, including without limitation books and records related to the production and sale of IGIV, Prolastin and Albumin. Any dispute as to the calculations in a Statement of Sales shall be resolved pursuant to Section 8.06. All capitalized terms used in this Section 5.03 and not defined herein have the meanings given such terms in Exhibit D.

SECTION 5.04 Confidentiality.

(a) The Bayer Parties from time to time will receive or have access to Confidential Information pursuant to this Agreement. “Confidential Information” means (i) all information, data, agreements, documents, reports and records which are oral or in writing containing information concerning the Company or its Affiliates or their businesses or assets, and (ii) all memoranda, notes, analyses, compilations, studies or other documents which include any such Confidential Information, whether prepared by the Company, a Bayer Party or their respective Affiliates, directors, employees, managers, members, partners, representatives or agents (including attorneys, consultants, lenders, potential investors and financial advisors) (collectively, “Representatives”); provided, however, that “Confidential Information” does not include (i) information which is obtained by such Bayer Party after the date hereof from a source other than the Company or its Affiliates or their respective Representatives, (ii) information which is or becomes generally available to the public other than as a result of a disclosure by a Bayer Party in violation of this Section 5.04, or (iii) information developed independently by a Bayer Party after the date hereof without use of the Confidential Information.

(b) No Bayer Party, nor any Affiliate of any Bayer Party, shall disclose or permit or cause to be disclosed any Confidential Information to any Person nor use any Confidential Information for its own purposes or its own account, except as provided in subsections (c) through (e) below and Section 5.02.

(c) A Bayer Party (a “Disclosing Party”) may disclose the Confidential Information to its Representatives who (x) need to know such information to permit its Representatives to review and evaluate such Disclosing Party’s investment in the Company, (y) are informed of the confidential nature of the Confidential Information and (z) agree to maintain the confidentiality of the Confidential Information. The Disclosing Party agrees to be fully responsible for any breach of this Section 5.04 by any of its Representatives.

(d) Notwithstanding anything to the contrary set forth in this Section 5.04, if a Bayer Party or any of its Representatives are required to disclose any Confidential Information

pursuant to any applicable law, rule or regulation or a subpoena, court order, similar judicial process, regulatory agency or stock exchange rule, such Bayer Party will, if possible, promptly notify the Company of any such requirement so that the Company may seek an appropriate protective order or waive compliance with the provisions of this Section 5.04. If such order is not obtained, such Bayer Party and its Representatives will disclose only that portion of the Confidential Information which they are advised by counsel that they are legally required to so disclose.

(e) Notwithstanding anything to the contrary set forth in this Section 5.04, the obligations of confidentiality contained herein, as they relate to each Bayer Party’s investment in the Company, shall not apply to the federal tax structure or federal tax treatment of each Bayer Party’s investment in the Company, and each of the Bayer Parties and their respective Affiliates may disclose to any and all persons or entities, without limitation of any kind, the federal tax structure and federal tax treatment of such Bayer Party’s investment in the Company. The preceding sentence is intended to cause each Bayer Party’s investment in the Company not to be treated as having been offered under conditions of confidentiality for purposes of Section 1.6011-4(b)(3) (or any successor provision) of the Treasury Regulations promulgated under Section 6011 of the Internal Revenue Code of 1986, as amended, and shall be construed in a manner consistent with such purpose. In addition, each of the parties hereto acknowledges that it has no proprietary or exclusive rights to the tax structure of each Bayer Party’s investment in the Company or any tax matter or tax idea related to any Bayer Party’s investment in the Company.

ARTICLE VI

REPRESENTATIONS

SECTION 6.01 Representations of the Company.

The Company represents and warrants that:

(a) Due Organization, Good Standing and Power. The Company is a corporation and is duly organized or formed, validly existing and in good standing under the laws of the state of Delaware. The Company has all requisite corporate or other power and authority to own or lease and to operate its assets and to conduct the business now being conducted by it. The Company is duly authorized, qualified or licensed to do business as a foreign corporation or other organization in good standing in each of the jurisdictions in which its ownership of property or the conduct of its business requires such authorization, qualification or licensing, except where the failure to have such authorization, qualification or licensing could not reasonably be expected to have a material adverse effect on the Company, or on the performance of its obligations hereunder. The Company has all requisite corporate or other power and authority under Applicable Law and its Charter Documents to enter into this Agreement and to perform its obligations hereunder.

(b) Authorization and Validity of Agreement. The execution and delivery of this Agreement by the Company and the performance by it of the obligations hereunder have been duly authorized and approved by all necessary corporate or other action under Applicable

Law and the relevant Charter Documents on the part of the Company and do not require the approval of the equity holders of the Company. This Agreement has been duly executed and delivered by the Company and constitutes the legal, valid and binding obligation of the Company enforceable against it in accordance with its terms, except as that enforceability may be (i) limited by any applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors’ rights generally, (ii) subject to general principles of equity (regardless of whether that enforceability is considered in a proceeding in equity or at law) and (iii) limited by general principles of Applicable Law regarding the enforceability of arbitral awards and judicial decisions.

(c) Lack of Conflicts. Neither the execution and delivery of this Agreement by the Company or the performance by the Company of its obligations hereunder does or will (i) conflict with, or result in the breach of any provision of, the Charter Documents of the Company, (ii) violate any Applicable Law or any permit, order, award, injunction, decree or judgment of any Governmental Authority applicable to or binding upon the Company or to which any of the properties or assets of the Company is subject or (iii) violate, conflict with or constitute a material breach or termination of, or give any Person the right to terminate, or constitute a material default, event of material default or an event that, with notice, lapse of time or both, would constitute a material default or event of material default, under the terms of any agreement to which the Company is party.

(d) No Consents. The execution and delivery of this Agreement by the Company and the performance by the Company of its obligations hereunder do not require any Governmental Approval. No consent (other than Governmental Approvals) will be required to be obtained by the Company for the performance of its obligations hereunder.

(e) Issued and Outstanding Shares. All of the issued and outstanding shares of Senior Convertible Preferred Stock issued to Talecris LLC and all of the issued and outstanding shares of Common Stock and Junior Preferred Stock issued to Bayer or its Affiliates on the Effective Date have been duly authorized and are validly issued, fully paid and non-assessable.

(f) Charter Documents. Attached hereto as Exhibit A, Exhibit B, Exhibit C and Exhibit D are true, complete and correct copies of the Company’s Certificate of Incorporation, Series A Senior Convertible Preferred Stock Designations, Series B Senior Convertible Preferred Stock Designations and Junior Preferred Stock Designations, respectively, certified as of a recent date by the Secretary of State of Delaware, none of which have been amended or modified since the date of such certification.

(g) Talecris LLC Contribution. The amount Talecris LLC contributed, directly or indirectly, to the Company on or prior to the Effective Time in exchange for Series A Senior Convertible Preferred Stock and Junior Secured Convertible Notes is $100 million. As of the Effective Time, Talecris LLC will not, and will have no rights to, receive other Equity Interests of the Company in exchange for such contributed amount. Attached hereto as Exhibit E are true, complete and correct copies of the Purchase Agreement and the Junior Secured Convertible Notes.

(h) Junior Preferred Stock. As of the Effective Time, Bayer will be the only holder of Junior Preferred Stock. So long as Bayer, any of its Permitted Transferees or any of its transferees which becomes a party to this Agreement pursuant to Section 3.06 holds outstanding shares of Junior Preferred Stock, the Company will not issue shares of Junior Preferred Stock to any Person other than Bayer.

SECTION 6.02 Representations of Talecris LLC.

Talecris LLC represents and warrants that:

(a) Due Organization, Good Standing and Power. Talecris LLC is a limited liability company and is duly organized or formed, validly existing and in good standing under the laws of the state of Delaware. Talecris LLC has all requisite company or other power and authority to own or lease and to operate its assets and to conduct the business now being conducted by it. Talecris LLC is duly authorized, qualified or licensed to do business as a foreign corporation or other organization in good standing in each of the jurisdictions in which its ownership of property or the conduct of its business requires such authorization, qualification or licensing, except where the failure to have such authorization, qualification or licensing could not reasonably be expected to have a material adverse effect on Talecris LLC or on the performance of its obligations hereunder. Talecris LLC has all requisite company or other power and authority under Applicable Law and its Charter Documents to enter into this Agreement and to perform its obligations hereunder.

(b) Authorization and Validity of Agreement. The execution and delivery of this Agreement by Talecris LLC and the performance by Talecris LLC of the obligations hereunder have been duly authorized and approved by all necessary company or other action under Applicable Law and the relevant Charter Documents on the part of Talecris LLC and do not require the approval of the equity holders of Talecris LLC. This Agreement has been duly executed and delivered by Talecris LLC and constitutes the legal, valid and binding obligation of Talecris LLC enforceable against it in accordance with its terms, except as that enforceability may be (i) limited by any applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors’ rights generally, (ii) subject to general principles of equity (regardless of whether that enforceability is considered in a proceeding in equity or at law) and (iii) limited by general principles of Applicable Law regarding the enforceability of arbitral awards and judicial decisions.

(c) Lack of Conflicts. Neither the execution and delivery of this Agreement by Talecris LLC or the performance by Talecris LLC of its obligations hereunder does or will (i) conflict with, or result in the breach of any provision of, the Charter Documents of Talecris LLC, (ii) violate any Applicable Law or any permit, order, award, injunction, decree or judgment of any Governmental Authority applicable to or binding upon Talecris LLC or to which any of the properties or assets of Talecris LLC is subject or (iii) violate, conflict with or constitute a material breach or termination of, or give any Person the right to terminate, or constitute a material default, event of material default or an event that, with notice, lapse of time or both, would constitute a material default or event of material default, under the terms of any agreement to which Talecris LLC is party.

(d) No Consents. The execution and delivery of this Agreement by Talecris LLC and the performance by Talecris LLC of its obligations hereunder do not require any Governmental Approval. No consent (other than Governmental Approvals) will be required to be obtained by Talecris LLC for the performance of their respective obligations hereunder.

(e) Talecris LLC Contribution. The amount Talecris LLC contributed, directly or indirectly, to the Company on or prior to the Effective Time in exchange for Series A Senior Convertible Preferred Stock and Junior Secured Convertible Notes is $100 million. As of the Effective Time, Talecris LLC will not, and will have no rights to, receive other Equity Interests of the Company in exchange for such contributed amount.

(f) Ownership. Cerberus and Ampersand collectively beneficially own 100% of the membership interests in Talecris LLC.

SECTION 6.03 Representations of Bayer.

Bayer represents and warrants that:

(a) Due Organization, Good Standing and Power. Bayer is a limited liability company duly organized, validly existing and in good standing under the laws of the state of Delaware. Bayer has all requisite company or other power and authority to own or lease and to operate its assets and to conduct the business now being conducted by it. Bayer is duly authorized, qualified or licensed to do business as a foreign corporation or other organization in good standing in each of the jurisdictions in which its ownership of property or the conduct of its business requires such authorization, qualification or licensing, except where the failure to have such authorization, qualification or licensing could not reasonably be expected to have a material adverse effect on Bayer or on the performance of its obligations hereunder. Bayer has all requisite company or other power and authority under Applicable Law and its Charter Documents to enter into this Agreement and to perform its obligations hereunder.

(b) Authorization and Validity of Agreement. The execution and delivery of this Agreement by Bayer and the performance of its obligations hereunder have been duly authorized and approved by all necessary company or other action under Applicable Law and the relevant Charter Documents on the part of Bayer and do not require the approval of the equity holders of Bayer. This Agreement has been duly executed and delivered by Bayer and constitutes the legal, valid and binding obligation of Bayer enforceable against it in accordance with its terms, except as that enforceability may be (i) limited by any applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors’ rights generally, (ii) subject to general principles of equity (regardless of whether that enforceability is considered in a proceeding in equity or at law) and (iii) limited by general principles of Applicable Law regarding the enforceability of arbitral awards and judicial decisions.

(c) Lack of Conflicts. Neither the execution and delivery of this Agreement by Bayer or the performance of its obligations hereunder does or will (i) conflict with, or result in the breach of any provision of, the Charter Documents of Bayer, (ii) violate any Applicable Law or any permit, order, award, injunction, decree or judgment of any Governmental Authority

applicable to or binding upon Bayer or to which any of its properties or assets is subject or (iii) violate, conflict with or constitute a material breach or termination of, or give any Person the right to terminate, or constitute a material default, event of material default or an event that, with notice, lapse of time or both, would constitute a material default or event of material default, under the terms of any agreement to which Bayer is party.

(d) No Consents. The execution and delivery of this Agreement by Bayer and the performance of its obligations hereunder do not require any Governmental Approval. No consent (other than Governmental Approvals) will be required to be obtained by Bayer for the performance of its obligations hereunder.

ARTICLE VII

INDEMNIFICATION

SECTION 7.01 Indemnification.

Subject to the provisions of Section 4.07 and Section 4.08:

(a) Indemnity by the Company. The Company shall indemnify and hold harmless the Bayer Parties and Talecris LLC against any and all Claims or Losses now existing or hereinafter arising, whether known or unknown, out of: (i) any inaccuracy in any of the representations or breach of any of the warranties made in this Agreement by the Company or (ii) any breach or default in performance of any of the obligations that are to be performed by the Company under this Agreement.

(b) Indemnity by Talecris LLC. Talecris LLC shall indemnify and hold harmless the Bayer Parties and the Company against any and all Claims or Losses now existing or hereinafter arising, whether known or unknown, out of: (i) any inaccuracy in any of the representations or breach of any of the warranties made in this Agreement by Talecris LLC or (ii) any breach or default in performance of any of the obligations that are to be performed by Talecris LLC under this Agreement.

(c) Indemnity by Bayer. The Bayer Parties shall indemnify and hold harmless the Company and Talecris LLC against any and all Claims or Losses now existing or hereinafter arising, whether known or unknown, out of: (i) any inaccuracy in any of the representations or breach of any of the warranties made in this Agreement by the Bayer Parties or (ii) any breach or default in performance of any of the obligations that are to be performed by the Bayer Parties under this Agreement.

(d) Survival. The right to indemnification under this Section shall survive indefinitely.

SECTION 7.02 Enforcing Claims Under Indemnity.

(a) If an Indemnified Party intends to seek indemnity under this Article 7, such Indemnified Party shall promptly notify the Indemnifying Party in writing of such Claims setting forth the amount of the Claim or Loss, if known, and the method of computation thereof,

if known, and containing a reference to the section of this Agreement under which the Indemnified Party seeks indemnification; provided, however, that the failure to provide such notice shall not affect the obligations of the Indemnifying Party unless it is actually prejudiced thereby. If the Indemnifying Party fails to grant the Indemnified Party with the indemnity requested, the Indemnified Party may seek to enforce this provision in accordance with Section 8.05.

(b) In the event such Claim involves a Claim by a third Person against the Indemnified Party, the Indemnifying Party shall have 30 days after receipt of such notice to decide whether it will undertake, conduct and control, through counsel of its own choosing and at its own expense, the settlement or defense thereof, and if it so decides, the Indemnified Party shall cooperate with it in connection therewith; provided, however, that the Indemnifying Party may so undertake, conduct and control the settlement or defense thereof only if it acknowledges in writing its indemnification obligations hereunder and the Indemnified Party may participate (subject to the Indemnifying Party’s control) in such settlement or defense through counsel chosen by it; provided, further that the fees and expenses of such Indemnified Party’s counsel shall be borne by the Indemnified Party. If the defendants in any action include the Indemnified Party and the Indemnifying Party, and the Indemnified Party shall have been advised by its counsel in writing that there are legal defenses available to the Indemnified Party which are materially different from or in addition to those available to the Indemnifying Party, the Indemnified Party shall have the right to employ its own counsel in such action, and, in such event, the reasonable fees and expenses of such counsel shall be borne by the Indemnifying Party. The Indemnifying Party may, without the consent of the Indemnified Party, settle or compromise or consent to the entry of any judgment in any action involving only the payment of money (A) which includes as an unconditional term thereof the delivery by the claimant or plaintiff to the Indemnified Party of a duly executed written release of the Indemnified Party from all Liability in respect of such action which written release shall be reasonably satisfactory in form and substance to the Indemnified Party and (B) if there is no finding or admission of any violation of law or any violation of any Person and no effect on any other Claims that may be made against the Indemnified Party. The Indemnifying Party shall not, without the written consent of the Indemnified Party, settle or compromise any action involving relief other than the payment of money in any manner that, in the reasonable judgment of the Indemnified Party, would materially and adversely affect the Indemnified Party; provided, however, that if the Indemnified Party shall fail or refuse to consent to a settlement, compromise or judgment proposed by the Indemnifying Party and approved by the third Person in any such action and a judgment thereafter shall be entered or a settlement or compromise thereafter shall be effected on terms less favorable in the aggregate to the Indemnified Party than the settlement, compromise or judgment proposed by the Indemnifying Party and approved by the third Person on such action, the Indemnifying Party shall have no Liability hereunder with respect to any Claim or Loss in excess of those that were provided for in such settlement, compromise or judgment so proposed by the Indemnifying Party or any costs or expenses related to such Claim arising after the date such settlement, compromise or judgment was so proposed. So long as the Indemnifying Party is diligently contesting any such Claim in good faith, the Indemnified Party shall not pay or settle any such Claim, unless such settlement includes as an unconditional term thereof the delivery by the claimant or plaintiff and by the Indemnified Party to the Indemnifying Party of duly executed written releases of the Indemnifying Party from all Liability in respect of such Claim which written releases shall be reasonably satisfactory in form and substance to the Indemnifying Party.

The Indemnified Party shall cooperate fully in all aspects of any investigation, defense, pre-trial activities, trial, compromise, settlement or discharge of any Claim in respect of which indemnification is sought pursuant to this Section 7.02. If the Indemnifying Party does not notify the Indemnified Party, within 30 days after the receipt of the Indemnified Party’s notice of a claim of indemnity hereunder, that it elects to undertake the defense thereof or does not acknowledge its indemnification obligations with respect thereto, the Indemnified Party shall have the right to contest, settle or compromise the Claim, but shall not thereby waive any right to indemnity therefor pursuant to this Agreement.

(c) The Indemnified Party shall cooperate with the Indemnifying Party in pursuing reasonable remedies against third parties, including any insurance carrier or potential indemnitor, other than the Indemnifying Party, to recover any Claim or Loss against the Indemnified Party; provided, however, the Indemnified Party shall only be required to initiate litigation or other formal claims procedure to seek remedies against such third parties when requested by the Indemnifying Party in the exercise of reasonable business judgment; provided, further, the Company shall only be required to participate as a party claimant against any of its customers where its participation is reasonably necessary to assure recovery of a Claim or Loss that the Company has demanded that Bayer is obligated to pay. All costs incurred by the Indemnified Party in pursuing such remedies at the request of the Indemnifying Party shall be borne by the Indemnifying Party. The Indemnifying Party shall not delay any payments due and owing the Indemnified Party under this Article 7 while Claims are being pursued against any third parties under this Section 7.02.

SECTION 7.03 Exclusive Remedies.

THE INDEMNIFICATION PROVISIONS IN THIS ARTICLE 7 SHALL BE THE SOLE AND EXCLUSIVE REMEDIES OF THE PARTIES FOR THE BREACH OF ANY REPRESENTATION OR WARRANTY IN THIS AGREEMENT AND FOR THE NON-PERFORMANCE OF ANY COVENANT AND AGREEMENT IN THIS AGREEMENT (ABSENT ACTUAL FRAUD). FOR THE CONSIDERATION PROVIDED HEREIN EACH PARTY HEREBY COVENANTS AND AGREES NOT TO ▇▇▇ ANY OTHER PARTY UPON ANY CLAIM, DEMAND, OR CAUSE OF ACTION RELATING TO THIS AGREEMENT, INCLUDING, WITHOUT LIMITATION, ANY CLAIM OR CAUSE OF ACTION FOR INDEMNITY OR CONTRIBUTION, ON ANY BASIS OTHER THAN PERMITTED UNDER THE TERMS PROVIDED IN THIS ARTICLE 7 (OTHER THAN A CLAIM BASED ON ACTUAL FRAUD).

SECTION 7.04 Treatment as Boot Adjustments.

Payments under this Article 7 shall for tax purposes be treated as an adjustment to the Boot and Contributed Cash in accordance with Article 3 of the Joint Contribution Agreement to the extent permitted by law.

ARTICLE VIII

MISCELLANEOUS

SECTION 8.01 Consent to Assignment.

This Agreement and all of the provisions hereof shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns, and it is not intended to confer upon any other person any rights or remedies hereunder. Neither this Agreement nor any of the rights, interests or obligations hereunder may be assigned by any of the parties without the prior written consent of the other party hereto, except that each party may at any time assign any or all of its rights or obligations hereunder to one of its wholly owned subsidiaries (but no such assignment shall relieve such party of any obligations under this Agreement). Notwithstanding the foregoing, the Company may assign this Agreement and any or all rights or obligations hereunder to (i) any Affiliate of the Company provided that any such Affiliate becomes a party to this Agreement, (ii) any lender of the Company as collateral security or (iii) any successor in interest to the Company; provided that any such successor becomes a party to this Agreement; provided that no assignment under (i), (ii) or (iii) above shall relieve the Company from any obligation hereunder. Any Bayer Party may assign this Agreement and any or all rights or obligations hereunder to (i) any Affiliate of Bayer to which a Bayer Party Transfers Common Shares in accordance with this Agreement, provided that any such Affiliate becomes a party to this Agreement or (ii) any successor in interest to such Bayer Party, provided that any such successor becomes a party to this Agreement; provided that no assignment under (i) or (ii) above shall relieve Bayer from any obligation hereunder. Talecris LLC may assign this Agreement and any or all rights or obligations hereunder to (i) any Affiliate of Talecris LLC to which Talecris LLC transfers Shares in accordance with this Agreement, provided that any such Affiliate becomes a party to this Agreement, and (ii) any successor in interest to Talecris LLC provided that any such assignee becomes a party to this Agreement; provided that no assignment under (i) or (ii) above shall relieve Talecris LLC from any obligation hereunder. Any purported assignment in contravention of this Section 8.01 shall be void.

SECTION 8.02 Entire Agreement and Amendments.

This Agreement constitutes the entire agreement among the parties, and merges and supersedes all previous agreements and understandings among the parties, whether oral or written, relating to the subject matter hereof. No amendment, modification or interpretation of this Agreement will have any effect unless it is reduced to writing, makes specific reference to this Agreement and is signed by all of the parties.

SECTION 8.03 Notices.

All notices, requests, demands and other communications required or permitted hereunder shall be in writing and if mailed by prepaid first-class mail or certified mail, return receipt requested, at any time other than during a general discontinuance of postal service due to strike, lockout or otherwise, shall be deemed to have been received on the earlier of the date shown on the receipt or three Business Days after the postmarked date thereof and, if telexed or telecopied, the original notice shall be mailed by prepaid first class mail within twenty-four (24)

hours after sending such notice by telex or telecopy, and shall be deemed to have been received on the next Business Day following dispatch and acknowledgment of receipt by the recipient’s telex or telecopy machine. In addition, notices hereunder may be delivered by hand, in which event the notice shall be deemed effective when delivered, or by overnight courier, in which event the notice shall be deemed to have been received on the next Business Day following delivery to such courier. All notices and other communications under this Agreement shall be given to the parties hereto at the following addresses:

(a)	If to the Company or Talecris LLC:

		c/o ▇▇▇▇ ▇▇▇▇▇▇▇▇
		General Counsel
		Cerberus Capital Management, L.P.
		▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇
		▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
		Fax: (▇▇▇) ▇▇▇-▇▇▇▇

		and

		c/o Talecris Biotherapeutics, Inc.
		▇.▇. ▇▇▇ ▇▇▇▇▇
		79 ▇▇ ▇▇▇▇▇▇▇▇▇ Drive
		4101 Research Commons
		▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇
		▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
		Fax: (▇▇▇) ▇▇▇-▇▇▇▇
		Attn: General Counsel

		With copies to:

		▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, Esq.
		▇▇▇▇▇▇▇▇ & ▇▇▇▇▇▇▇▇ LLP
		▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇
		▇▇▇▇▇ ▇▇▇▇
		▇▇▇ ▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
		Fax: (▇▇▇) ▇▇▇-▇▇▇▇

		and

		▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇, Esq.
		▇▇▇▇▇▇ & ▇▇▇▇▇▇▇ LLP
		▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇.▇.
		▇▇▇▇▇ ▇▇▇▇
		▇▇▇▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇
		Fax: (▇▇▇) ▇▇▇-▇▇▇▇

		and

		▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
		Managing General Partner
		Ampersand Ventures
		▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇
		▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
		Fax: (▇▇▇) ▇▇▇-▇▇▇▇

(b)	If to any Bayer Party:

		▇▇▇▇ ▇. ▇▇▇▇▇
		Vice President, General Counsel and Secretary
		Bayer HealthCare LLC
		▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇
		▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇-▇▇▇▇
		Fax: (▇▇▇) ▇▇▇-▇▇▇▇

		With a copy to:

		▇▇▇▇▇▇▇ ▇▇▇▇▇▇
		Fulbright & ▇▇▇▇▇▇▇▇ L.L.P.
		▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇.▇.
		▇▇▇▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇
		Fax: (▇▇▇) ▇▇▇-▇▇▇▇

Any party hereto may change its address specified for notices herein by designating a new address by notice in accordance with this Section 8.03.

SECTION 8.04 Non-Waiver.

The waiver by any party of any breach of any term, covenant, condition or agreement contained herein or any default in the performance of any obligations hereunder shall not be deemed to be a waiver of any other breach or default of the same or of any other term, covenant, condition, agreement or obligation.

SECTION 8.05 Governing Law, Jurisdiction.

(a) This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, without regard to conflict of laws principles.

(b) Subject to Section 8.06, each of the parties hereto hereby irrevocably and unconditionally submits, for itself and its property, to the jurisdiction of any Delaware State court or federal court of the United States of America sitting in Delaware, and any appellate court thereof, in any action or proceeding arising out of or relating to this Agreement, or for recognition or enforcement of any judgment, and each of the parties hereto hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined in any such Delaware State court or, to the extent permitted by law, in such federal court. Each of the parties agrees that any action or proceeding arising out of or

relating to this Agreement that is subject to the jurisdiction of the Delaware Superior Court rather than the Delaware Chancery Court shall be conducted by Summary Proceedings.

SECTION 8.06 Dispute Resolution of Accounting Matters.

In the event that Bayer disputes the Company’s calculations of the Bayer Equity Fair Market Value under Section 2.01(h) or any of the calculations under Section 5.03, it shall, within 30 days of the Election Time or delivery of the Statement of Sales, as applicable, deliver a written notice to the Company (the “Dispute Notice”) setting forth in reasonable detail the basis of such dispute. In the event that the Dispute Notice is so delivered, the parties shall negotiate to attempt to resolve the dispute. If the parties fail to resolve any such dispute within 20 days after receipt of any Dispute Notice, a firm of independent certified public accountants of national standing mutually and reasonably agreeable to the Company and Bayer (the “Reviewing Accountant”) will review the dispute. The parties shall make available to the Reviewing Accountant all work papers and all other information and material in their possession relating to the matters asserted in the Dispute Notice. The Reviewing Accountant shall be instructed by the parties to use its best efforts to deliver to the parties its determination as promptly as practicable after such submission of the dispute to the Reviewing Accountant. The determination of the Reviewing Accountant shall be final and binding on the parties. Each party shall bear its own expenses and the fees and expenses of its own representatives and experts, including its independent accountant, in connection with the preparation, review, dispute (if any) and final determination of the Bayer Equity Fair Market Value and Annual Net Sales, Annual Achievements and Annual Reductions. The Company and Bayer shall share equally in the costs, expenses and fees of the Reviewing Accountant.

SECTION 8.07 Captions.

All captions are inserted for convenience only, and will not affect any construction or interpretation of this Agreement.

SECTION 8.08 Severability.

Any provision of this Agreement which is or may become prohibited or unenforceable, as a matter of law or regulation, will be ineffective only to the extent of such prohibition or unenforceability and shall not invalidate the remaining provisions hereof if the essential purposes of this Agreement may be given effect despite the prohibition or unenforceability of the affected provision.

SECTION 8.09 Defined Terms.

Defined terms used but not otherwise defined in this Agreement shall have the meaning ascribed to those terms in the Joint Contribution Agreement or the Junior Preferred Stock Designations, as applicable.

SECTION 8.10 Set-Off.

No party to this Agreement shall have any right of set off with respect to amounts it has an obligation to pay hereunder.

SECTION 8.11 Counterparts.

This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original, and all of which together shall be deemed to be one and the same instrument.

SECTION 8.12 Recapitalizations, Exchanges, Etc. Affecting Common Stock.

Except as otherwise provided in this Agreement, the provisions of this Agreement shall apply to any and all shares of capital stock or other securities of the Company or any successor or assign of the Company (whether by merger, consolidation, sale of assets, transfer of Equity Interests or otherwise) which may be issued in respect of, in exchange for, or in substitution of, any Shares by reason of any reorganization, recapitalization, reclassification, merger, consolidation, partial or complete liquidation, sale of assets, spin-off, stock dividend, split, distribution to stockholders or combination of the Shares or any other change in the Company’s capital structure, in order to preserve fairly and equitably as far as practicable, the original rights and obligations of the parties hereto under this Agreement.

SECTION 8.13 Junior Preferred Stock.

The Allocation Schedule, the Capital Expenditures Schedule, the Production Capacity Schedule and the Yield Schedule, as each such term is defined in the Junior Preferred Stock Designations, are set forth in Exhibit F, Exhibit G, Exhibit H and Exhibit I, respectively. Solely for purposes of illustrating the various calculations set forth in the Junior Preferred Stock Designations, and not intending to limit any of the terms and conditions thereof, set forth in Appendix I are examples of calculations of the Liquidation Value, Special Liquidation Value and Deemed Liquidation Value, and related amounts, under the scenarios described therein.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories thereunto duly authorized as of the day and year first above written.

TALECRIS BIOTHERAPEUTICS HOLDINGS CORP.


By:	/s/ ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇
	Name:	▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇
	Title:	Executive Chairman, President
		and Chief Executive Officer

TALECRIS HOLDINGS, LLC


By:	/s/ ▇▇▇▇ ▇. ▇▇▇▇▇▇▇
	Name:	▇▇▇▇ ▇. ▇▇▇▇▇▇▇
	Title:	Vice President

BAYER HEALTHCARE LLC


By:	/s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇
	Name:	▇▇▇▇▇▇ ▇. ▇▇▇▇▇
	Title:	Executive Vice President


By:	/s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇
	Name:	▇▇▇▇▇ ▇. ▇▇▇▇▇▇
	Title:	Assistant Secretary

SCHEDULE I

AFFILIATES OF BAYER HEALTHCARE LLC

None

SCHEDULE II

TALECRIS BIOTHERAPEUTICS HOLDINGS CORP.

Initial Capitalization

		Issuable in Bayer Acquisition				Issuable in Precision Acquisition
				Convertible from	Convertible from		Convertible from
	Authorized	Actual		Series A(1)	Junior Notes(2)	Actual	Series B(1)
Common Stock ($0.01 par value)	100,000,000	1,000,000		900,000	8,100,000	—	1,730,790
Preferred Stock ($0.01 par value):	10,000,010
Series A Senior Convertible(3)	5,000,000	100,000		—	900,000	—	—
Series B Senior Convertible(3)	5,000,000	—		—	—	192,310	—
Junior	10	1		—	—	—	—
Junior Secured Convertible Notes		$	90,000,000	—	—	—	—

(1)	The conversion rate is 9 shares of Common Stock per share of Series A or Series B Senior Convertible Preferred Stock.
(2)	The conversion rate is 10 shares of Series A Senior Convertible Preferred Stock per $1,000 principal amount of Junior Secured Convertible Notes.
(3)	Liquidation preference is $100 per share.

STOCKHOLDERS AGREEMENT among TALECRIS BIOTHERAPEUTICS HOLDINGS CORP. TALECRIS HOLDINGS, LLC and BAYER HEALTHCARE LLC AND ITS AFFILIATES PARTY HERETO Dated as of March 31, 2005

Document Metadata

Document Metadata

Table of Contents